Ocean Power Technologies, whose wave power technology is brilliantly realized in their utility-scale PowerBuoy® wave generation system, was quite pleased to announce reception of a major contract today with a top Japanese engineering company that really has the pull, as well as the sea legs needed to act as a transformative industry influence in this area, Mitsui Engineering & Shipbuilding (MES). Valued at $2.6M, this contract covers the final design and component aspects for a PowerBuoy system that is going in off the coast and which will demonstrate the efficacy of this technology in helping to satisfy the Japanese Environment Minister’s strategic intention to increase the nation’s renewable energy inputs by as much as six times in the coming years.
In fact, wave energy has been specifically earmarked by the Japanese government as a primary component of their renewables policy, and they have targeted around 1.5k MW of new wave and tidal generation capacity by 2030. Hirotaka Ohashi, Deputy Director of Business Development and Innovation Hq. for MES, referencing the 2011 earthquake and subsequently devastating impact to Japan’s nuclear industry and energy market, recently assured investors that the company would be working hand-in-hand with OPTT to commercialize this revolutionary generation tech and emphasized his respect for the position the PowerBuoy already holds within the market. Bold words from such an eminent engineering firm with an established track record in ship/ocean systems and a strong endorsement in general for the success of this partnership, especially considering the many years of collaborative work already built up between the two companies. MES will be in charge of doing the requisite moorings and the actual deployment of the system.
This latest contract is a natural progression from the previously announced preliminary design and development work that was done earlier in the year and the contract is provided under the (Oct 24) cooperation agreement aimed at bringing the technology to fruition in Japan, as well as six other international markets. Key objectives of the new contract will be to test out the core structural element of the PowerBuoy, the spar, against the specific conditions of the target environment and to finalize its design, as well as that of the power take-off component which houses the generator and main electronics.
Once tweaked for Japanese wave conditions, this design (which can automatically shut itself off into a fixed lockout mode using onboard sensors arrays in the event of extremely large waves) will serve as a platform for rolling out commercial-scale ocean trials later on and paving the way for wave power utilities. Estimates are set for March of 2015 to complete this latest phase of work and a deployment phase should commence almost immediately thereafter.
CEO of OPTT, Charles F. Dunleavy, hailed this next important step on the road to commercial-scale wave power for the Japanese as a real boon for the nation and underscored the significance of the tight-knit relationship between OPTT and MES, both in Japan and now in several other countries as well. Dunleavy also expressed supreme confidence in the world-class fabrication facilities and experience possessed by MES, assuring investors that the majority of PowerBuoy system components, which are set to be manufactured by Mitsui in Japan, will meet with the company’s exacting specifications.
The simple, rugged steel construction of the PowerBuoy and its low surface profile (almost invisible from shore), combined with the product’s ability to utilize conventional mooring systems, makes it a highly scalable (buoys are distributed across an area at intervals like gas wells for maximum efficiency) and attractive solution that could make 100+ MW wave energy utility stations a prominent piece of the global energy puzzle.
Learn more by visiting Ocean Power Technologies at www.OceanPowerTechnologies.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, October 31, 2013
NCI, Inc. (NCIT) Awarded Headquarters Marine Corps Information Technology Functional Services and Support Contract Worth $7.9 Million
NCI, a supplier of cutting-edge enterprise services and solutions to Defense, Intelligence, Healthcare, and Civilian Government agencies worldwide, announced today that the company has received a $7.9 million contract to provide IT support to over 2,500 users worldwide from Headquarters Marine Corps Information Technology Functional Services and Support (HQMC IT FSS). The contract includes four option years on top of the initial base year.
The contract stipulates that NCI will supply comprehensive IT support for the HQMC Administration and Resource Management Division. This first class service will feature custom-developed and configured SharePoint applications and solutions, custom .NET application support, and Lotus Notes support and replacement. NCI has been supplying similar services to HQMC for several years, and this most recent contract is evidence of the quality of their service.
“Because NCI has been providing critical services and solutions to HQMC for the last five years, we are poised to capitalize on new innovations and technologies for HQMC’s future success,” said Brian Clark, NCI’s President. “NCI will ensure HQMC’s success by leveraging existing tools to reduce cost and ensure outstanding enterprise IT services and solutions. We look forward to continuing our strong partnership with the Marine Corps to achieve its mission objectives.”
For further information, please visit www.nciinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The contract stipulates that NCI will supply comprehensive IT support for the HQMC Administration and Resource Management Division. This first class service will feature custom-developed and configured SharePoint applications and solutions, custom .NET application support, and Lotus Notes support and replacement. NCI has been supplying similar services to HQMC for several years, and this most recent contract is evidence of the quality of their service.
“Because NCI has been providing critical services and solutions to HQMC for the last five years, we are poised to capitalize on new innovations and technologies for HQMC’s future success,” said Brian Clark, NCI’s President. “NCI will ensure HQMC’s success by leveraging existing tools to reduce cost and ensure outstanding enterprise IT services and solutions. We look forward to continuing our strong partnership with the Marine Corps to achieve its mission objectives.”
For further information, please visit www.nciinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Recovery Energy, Inc. (RECV) Granted Participation in New Well Adjacent to Leasehold, Wattenberg Prospects Looking Hot, Drilling Slated for Q1
Recovery Energy, which controls some 125k gross acres (112k net) of mostly long-term leases on highly concentrated and largely contiguous sites in Colorado, Nebraska and Wyoming, where the company has executed a pure play strategy focused on the prolific formations in the Denver-Julesburg (DJ) Basin, reported today that they are participating in PDC Energy’s new Richter #34M-203 horizontal well, drilled immediately adjacent to RECV’s North Wattenberg prospect.
Currently RECV is doing production and cash flow from the Cretaceous “J” Sandstone, but they also has a spectrum of unconventional horizons, including the Niobrara Oil Shale and Codell Sandstone to choose from (also the Permian Admire and Pennsylvanian Desmoines), with strong prospectivity for other hydrocarbon formations like the conventional Wykert Sandstone. PDC’s Richter #34M-203 is targeting the Niobrara “B” Bench and is one of a series of such wells (RECV has no working interest participation in the other wells) being drilled in the eastern half of the section from the pad, wells which also have targets in the Codell.
This is a nice feather in RECV’s cap that establishes the value of their leasehold and the company has been granted working interest here due to the proximity of the Richter #34M-203 wellbore path as per COGCC stipulations (Colorado Oil & Gas Conservation Commission). With Q4 this year slated for completion of the new well, which was sunk to a depth of just over 11.8k feet, Recovery Energy’s half of the section is now looking seriously hot.
President of RECV, Avi Mirman, pegged Q1 2014 for joint operations to be underway on their half of the section and also praised the logistical sophistication of PDC’s extensive development activities in the DJ Basin thus far, clearly encouraged by RECV’s chance to participate in the well and by the obvious implications for the company’s own production potential here. With a multiplicity of conventional and unconventional targets already identified on the company’s leasehold, this participation reinforces RECV’s strategy of advancing via low-risk opportunities in the region. Given the serious technological leaps in 3D seismic analysis and multi-stage fracking, the DJ Basin has really opened up in recent years and RECV has an impressive eight plus decades of experience in their management team, spanning all aspects of the industry to capitalize on as the ball keeps rolling.
Big news for the company’s North Wattenberg prospect and today’s announcement comes shortly after their report of having finalized agreements to increase working interest participation in the South Wattenberg prospect 320-acre spacing unit (where drilling is also set to commence in Q1 next year) to 63%. RECV anticipates a 14 to 18 well program in total between their two primary Wattenberg prospects and the potential upside here from a fusion of ongoing/successful conventional production and an unconventional drilling program with established targets, should really turn the heads of potential investors.
To get a closer look at Recovery Energy, Inc. visit www.RecoveryEnergyCo.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Currently RECV is doing production and cash flow from the Cretaceous “J” Sandstone, but they also has a spectrum of unconventional horizons, including the Niobrara Oil Shale and Codell Sandstone to choose from (also the Permian Admire and Pennsylvanian Desmoines), with strong prospectivity for other hydrocarbon formations like the conventional Wykert Sandstone. PDC’s Richter #34M-203 is targeting the Niobrara “B” Bench and is one of a series of such wells (RECV has no working interest participation in the other wells) being drilled in the eastern half of the section from the pad, wells which also have targets in the Codell.
This is a nice feather in RECV’s cap that establishes the value of their leasehold and the company has been granted working interest here due to the proximity of the Richter #34M-203 wellbore path as per COGCC stipulations (Colorado Oil & Gas Conservation Commission). With Q4 this year slated for completion of the new well, which was sunk to a depth of just over 11.8k feet, Recovery Energy’s half of the section is now looking seriously hot.
President of RECV, Avi Mirman, pegged Q1 2014 for joint operations to be underway on their half of the section and also praised the logistical sophistication of PDC’s extensive development activities in the DJ Basin thus far, clearly encouraged by RECV’s chance to participate in the well and by the obvious implications for the company’s own production potential here. With a multiplicity of conventional and unconventional targets already identified on the company’s leasehold, this participation reinforces RECV’s strategy of advancing via low-risk opportunities in the region. Given the serious technological leaps in 3D seismic analysis and multi-stage fracking, the DJ Basin has really opened up in recent years and RECV has an impressive eight plus decades of experience in their management team, spanning all aspects of the industry to capitalize on as the ball keeps rolling.
Big news for the company’s North Wattenberg prospect and today’s announcement comes shortly after their report of having finalized agreements to increase working interest participation in the South Wattenberg prospect 320-acre spacing unit (where drilling is also set to commence in Q1 next year) to 63%. RECV anticipates a 14 to 18 well program in total between their two primary Wattenberg prospects and the potential upside here from a fusion of ongoing/successful conventional production and an unconventional drilling program with established targets, should really turn the heads of potential investors.
To get a closer look at Recovery Energy, Inc. visit www.RecoveryEnergyCo.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Real Goods Solar (RSOL) Completes 2.2 MW Vermont Solar Farm Ahead of Schedule
Ahead of schedule, RGS Energy, the commercial and utility division of Real Goods Solar, has completed a new 2.2 MW solar farm in conjunction with St. Albans Solar Partners LLC. Located in St. Albans, Vt., the PV system is anticipated to generate around 3.1 million kWh each year, which is enough energy to power more than 400 homes.
A fixed array ground mount solar system, the new solar farm will eliminate more than 123 million pounds of carbon dioxide emissions over a 25-year period – the equivalent of planting more than 1.4 million trees. The system will also deliver environmental benefits to Vermont, helping the state reach its goal of 20 percent renewable energy by the year 2017.
All of the solar energy produced by the new system will be purchased through a feed-in tariff under the Standard Offer Program of Vermont’s Sustainably Priced Energy Development (SPEED) program, which was created by legislation in 2005 to stimulate renewable energy development in Vermont and help the state reach its renewable energy goals.
For more information, visit the Real Goods Solar Web site at www.RealGoodsSolar.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
A fixed array ground mount solar system, the new solar farm will eliminate more than 123 million pounds of carbon dioxide emissions over a 25-year period – the equivalent of planting more than 1.4 million trees. The system will also deliver environmental benefits to Vermont, helping the state reach its goal of 20 percent renewable energy by the year 2017.
All of the solar energy produced by the new system will be purchased through a feed-in tariff under the Standard Offer Program of Vermont’s Sustainably Priced Energy Development (SPEED) program, which was created by legislation in 2005 to stimulate renewable energy development in Vermont and help the state reach its renewable energy goals.
For more information, visit the Real Goods Solar Web site at www.RealGoodsSolar.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Jameson Stanford Resources (JMSN) Unearths Three Mining Sites for Long-term Growth Potential
Based out of Nevada, Jameson Stanford Resources is a metals and minerals exploration, development, and production company. Its focuses are on acquisitions and consolidations of mining claims, mineral leases, producing mines, and historical mines that it has identified as having profit and production potential.
Currently the company owns and operates mines in the Star Mountain Mining District in Beaver County, the Spor Mountain Mining District in Juab County, and the Ogden Bay area in Weber County, which are located in western or northern Utah. Its operations are centered upon initiating, producing, and expanding its current and future mineral holdings into quality assets that exhibit long-term growth potential. Below are in-depth descriptions of the sites at which Jameson Stanford is current active.
1) Star Mountain (located in the Star Mountain Mining District)—This project consists of 117 lode mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah. Based on extensive company exploration, testing, and analysis, the company estimates that the total inferred reserves at this site may be more than 100,000,000 metric tons of copper ore, as well as additional precious and base metals.
2) Spor Mountain (located in the Spor Mountain Mining District)—The Spor Mountain project consists of nine lode mining claims and three metalliferous mineral lease sections situated in Juab County, Utah. The company’s own Spor Mountain/Dugway Minerals project encompasses a total area of 2,098 acres. Drawing from indicators and data collected and acquired during preliminary analysis and two prospect pit excavations, there might be around 4,000,000 ounces of silver, commercial concentrations of beryllium, and other precious and base metals up for possible excavation.
3) Odgen Bay Minerals (located in West Odgen Area)—This area represents an in-development mineral excavation project on federal protected wetlands and river systems across 25 square miles of land. It is known as North Delta, which is located in West Odgen, Utah. The State of Utah Division of Natural Resources, USDA Natural Resources Conservation Service, and Weber County Emergency Management commissioned Jameson Stanford for restoration of wildlife habitats, damage repairs, dredging of silt and sand, and removal of debris from the Weber River. This project includes alluvia mineral deposits that are created and then replenished from the river flow of the close-by Wasatch Mountain Range. The deposits contain elements of commercial-grade zircon, usable silica, and other valuable heavy mineral ores.
More information about Jameson Stanford’s current activities and initiatives can be found at www.jamesonstanford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Currently the company owns and operates mines in the Star Mountain Mining District in Beaver County, the Spor Mountain Mining District in Juab County, and the Ogden Bay area in Weber County, which are located in western or northern Utah. Its operations are centered upon initiating, producing, and expanding its current and future mineral holdings into quality assets that exhibit long-term growth potential. Below are in-depth descriptions of the sites at which Jameson Stanford is current active.
1) Star Mountain (located in the Star Mountain Mining District)—This project consists of 117 lode mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah. Based on extensive company exploration, testing, and analysis, the company estimates that the total inferred reserves at this site may be more than 100,000,000 metric tons of copper ore, as well as additional precious and base metals.
2) Spor Mountain (located in the Spor Mountain Mining District)—The Spor Mountain project consists of nine lode mining claims and three metalliferous mineral lease sections situated in Juab County, Utah. The company’s own Spor Mountain/Dugway Minerals project encompasses a total area of 2,098 acres. Drawing from indicators and data collected and acquired during preliminary analysis and two prospect pit excavations, there might be around 4,000,000 ounces of silver, commercial concentrations of beryllium, and other precious and base metals up for possible excavation.
3) Odgen Bay Minerals (located in West Odgen Area)—This area represents an in-development mineral excavation project on federal protected wetlands and river systems across 25 square miles of land. It is known as North Delta, which is located in West Odgen, Utah. The State of Utah Division of Natural Resources, USDA Natural Resources Conservation Service, and Weber County Emergency Management commissioned Jameson Stanford for restoration of wildlife habitats, damage repairs, dredging of silt and sand, and removal of debris from the Weber River. This project includes alluvia mineral deposits that are created and then replenished from the river flow of the close-by Wasatch Mountain Range. The deposits contain elements of commercial-grade zircon, usable silica, and other valuable heavy mineral ores.
More information about Jameson Stanford’s current activities and initiatives can be found at www.jamesonstanford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CytRX Corp. (CYTR) Reports Further Developments in Global Phase 2b Trial
CytRX Corp., a biopharmaceutical research and development company specializing in oncology, today released further clinical data from a multi-site global Phase 2b study comparing its aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS) versus the widely used chemotherapeutic agent doxorubicin. The data will be presented today at the 18th Annual Connective Tissue Oncology Society Meeting at the Sheraton New York Times Square Hotel in New York City, NY. It will include additional information that was collected and recorded September 27 to October 16, 2013.
Still ongoing, the study had 47 remaining active patients in the clinical trial as of October 16, 2013 (36 on aldoxorubicin and 11 on doxorubicin). CYTR expects it will report top-line progression-free survival results for the trial sometime in December 2013.
“We are very pleased with the continued clinical findings from our global Phase 2b trial with aldoxorubicin as a first-line treatment in advanced soft tissue sarcomas, and the strength of the data presented today reinforces our belief that the linker technology platform can be applied to a broad range of cancer treatments,” said CYTR President and CEO Steven A. Kriegsman. “We look forward to advancing our aldoxorubicin second-line program into a Phase 3 pivotal trial in the first quarter of 2014 as well as evaluating aldoxorubicin as treatment for malignant glioblastoma (brain cancer) and HIV-related Kaposi’s sarcoma.”
In the trial 123 patients aged 18-80 years with histologically confirmed metastatic, locally advanced or unresectable soft tissue sarcomas were randomized 2:1 to receive 350 mg/m2 aldoxorubicin (260 mg/m2 doxorubicin equivalents) IV or 75 mg/m2 doxorubicin IV. They were slated to receive those dosages every three weeks for up to six cycles. The presented findings indicate ldoxorubicin can be administered at doses greater than 3 1/2 x the standard doxorubicin dose with similar or fewer systemic side effects. A significantly higher percentage of patients receiving aldoxorubicin are still active, have received at least 4 or 6 cycles of treatment, and have a greater number of tumor responses and stable disease. Patients in the trial treated with ldoxorubicin had a higher Overall Response Rate (ORR) (22%) compared with those treated with doxorubicin (0%) (p=0.004). In addition, a lower percentage of patients treated with aldoxorubicin (32%) showed progressive disease compared with patients treated with doxorubicin (50%) at the time of analysis.
The findings further showed 24 serious adverse effects associated with aldoxorubicin therapy patients as opposed to 6 serious adverse effects with doxorubicin-receiving patients. All of these effects were resolved and did not require treatment discontinuation. One treatment-related death in a patient treated with doxorubicin was reported.
A higher percentage of aldoxorubicin patients completed four cycles of treatment compared with doxorubicin patients (59 vs. 22, respectively) and six cycles of treatment (45 vs. 14, respectively). A similar percentage of aldoxorubicin patients (15%) and doxorubicin patients (16%) experienced neutropenic fever, and a higher percentage of doxorubicin patients (22%) had decreased cardiac output compared with aldoxorubicin patients (11%), as measured by a 15% decrease in left ventricular ejection fraction. No patient treated with aldoxorubicin had ejection fractions below 50% of their institutional norm versus 9.4% of patients that had received doxorubicin. Most importantly, there was no clinically significant reduction in cardiac function in the aldoxorubicin patients despite receiving 3 ½ times the standard dose of doxorubicin.
More information regarding CYTR, its initiatives, and the scientific background of its efforts can be found at: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Still ongoing, the study had 47 remaining active patients in the clinical trial as of October 16, 2013 (36 on aldoxorubicin and 11 on doxorubicin). CYTR expects it will report top-line progression-free survival results for the trial sometime in December 2013.
“We are very pleased with the continued clinical findings from our global Phase 2b trial with aldoxorubicin as a first-line treatment in advanced soft tissue sarcomas, and the strength of the data presented today reinforces our belief that the linker technology platform can be applied to a broad range of cancer treatments,” said CYTR President and CEO Steven A. Kriegsman. “We look forward to advancing our aldoxorubicin second-line program into a Phase 3 pivotal trial in the first quarter of 2014 as well as evaluating aldoxorubicin as treatment for malignant glioblastoma (brain cancer) and HIV-related Kaposi’s sarcoma.”
In the trial 123 patients aged 18-80 years with histologically confirmed metastatic, locally advanced or unresectable soft tissue sarcomas were randomized 2:1 to receive 350 mg/m2 aldoxorubicin (260 mg/m2 doxorubicin equivalents) IV or 75 mg/m2 doxorubicin IV. They were slated to receive those dosages every three weeks for up to six cycles. The presented findings indicate ldoxorubicin can be administered at doses greater than 3 1/2 x the standard doxorubicin dose with similar or fewer systemic side effects. A significantly higher percentage of patients receiving aldoxorubicin are still active, have received at least 4 or 6 cycles of treatment, and have a greater number of tumor responses and stable disease. Patients in the trial treated with ldoxorubicin had a higher Overall Response Rate (ORR) (22%) compared with those treated with doxorubicin (0%) (p=0.004). In addition, a lower percentage of patients treated with aldoxorubicin (32%) showed progressive disease compared with patients treated with doxorubicin (50%) at the time of analysis.
The findings further showed 24 serious adverse effects associated with aldoxorubicin therapy patients as opposed to 6 serious adverse effects with doxorubicin-receiving patients. All of these effects were resolved and did not require treatment discontinuation. One treatment-related death in a patient treated with doxorubicin was reported.
A higher percentage of aldoxorubicin patients completed four cycles of treatment compared with doxorubicin patients (59 vs. 22, respectively) and six cycles of treatment (45 vs. 14, respectively). A similar percentage of aldoxorubicin patients (15%) and doxorubicin patients (16%) experienced neutropenic fever, and a higher percentage of doxorubicin patients (22%) had decreased cardiac output compared with aldoxorubicin patients (11%), as measured by a 15% decrease in left ventricular ejection fraction. No patient treated with aldoxorubicin had ejection fractions below 50% of their institutional norm versus 9.4% of patients that had received doxorubicin. Most importantly, there was no clinically significant reduction in cardiac function in the aldoxorubicin patients despite receiving 3 ½ times the standard dose of doxorubicin.
More information regarding CYTR, its initiatives, and the scientific background of its efforts can be found at: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
LoJack Corp. (LOJN) Launches Fleet Referral Program for Auto Dealerships
Yesterday, vehicle fleet management and security provider LoJack announced that it has launched a Fleet Referral Program for auto dealerships. The program is designed to help dealers capitalize on the fleet management market by incentivizing and supporting sales of LoJack Fleet Management Powered by TomTom.
Earlier this year, LoJack and TomTom Business Solutions announced a strategic alliance to introduce an advanced fleet management offering. This powerful solution has provided LoJack customers with the opportunity to manage their fleets with lower operating costs and enhanced control. LoJack Fleet Management accommodates fleets of all sizes, includes a customized web interface, comprehensive reporting capabilities, access to a mobile application for fleet managers and vehicle operators, and more.
To participate in this program, dealers simply need to inform their fleet customers about LoJack Fleet Management and enter an interested customer’s contact information into a secure website administered by LoJack. A representative of LoJack will follow-up with the customer and will pay the dealer a referral fee for each new subscription purchased.
Industry experts estimate the fleet market to be worth almost $11 billion. With a forecasted increase in global fleet size and new focus on optimized operations, the industry is expected to grow to over $30 billion by 2018. In order to meet these growing demands, LoJack has recently expanded its internal sales team with representatives who understand the fleet industry’s demands and how LoJack Fleet Management Powered by TomTom can help a dealer’s business.
“We introduced LoJack Fleet Management to provide fleet managers with the business intelligence to drive improved operational efficiencies,” said Hal Dewsnap, LoJack’s Senior Vice President and General Manager of U.S. Sales. “Now, with our Fleet Referral Program, we are offering our dealer partners the incentives and tools they need to support their customers who own or manage a fleet.”
For more information about the LoJack Fleet Referral Program, please visit http://lojack.com/fleetreferral/overview
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Earlier this year, LoJack and TomTom Business Solutions announced a strategic alliance to introduce an advanced fleet management offering. This powerful solution has provided LoJack customers with the opportunity to manage their fleets with lower operating costs and enhanced control. LoJack Fleet Management accommodates fleets of all sizes, includes a customized web interface, comprehensive reporting capabilities, access to a mobile application for fleet managers and vehicle operators, and more.
To participate in this program, dealers simply need to inform their fleet customers about LoJack Fleet Management and enter an interested customer’s contact information into a secure website administered by LoJack. A representative of LoJack will follow-up with the customer and will pay the dealer a referral fee for each new subscription purchased.
Industry experts estimate the fleet market to be worth almost $11 billion. With a forecasted increase in global fleet size and new focus on optimized operations, the industry is expected to grow to over $30 billion by 2018. In order to meet these growing demands, LoJack has recently expanded its internal sales team with representatives who understand the fleet industry’s demands and how LoJack Fleet Management Powered by TomTom can help a dealer’s business.
“We introduced LoJack Fleet Management to provide fleet managers with the business intelligence to drive improved operational efficiencies,” said Hal Dewsnap, LoJack’s Senior Vice President and General Manager of U.S. Sales. “Now, with our Fleet Referral Program, we are offering our dealer partners the incentives and tools they need to support their customers who own or manage a fleet.”
For more information about the LoJack Fleet Referral Program, please visit http://lojack.com/fleetreferral/overview
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics, Inc. (VSTA) Addressing Costly, Far-Reach Neuropathic Pain Condition with Development of Lead Candidate AV-101
Neuropathic pain is a serious and chronic condition that affects millions of people around the world. This pain follows damage or disease of the peripheral or nervous system, resulting in a variety of abnormal sensations such as the feeling of electric shock, burning or coldness, numbness and itching, or “pins and needles.”
Recent market research estimates that more than 1.5 billion people worldwide are afflicted with neuropathic pain, costing the U.S. public health system alone between $560 billion – $635 billion annually, according to the American Academy of Pain Medicine.
Small-cap company VistaGen Therapeutics’ lead small molecule drug candidate, AV-101, is being developed in the United States for the treatment of neuropathic pain. AV-101 is also being developed for additional indications, such as depression and other neurological indications.
To-date, the company has been awarded more than $8.8 million from the National Institute of Health for the development of this treatment.
In preclinical studies, AV-101 demonstrated positive levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier, and preferential conversion into 7-CKYNA at the site of the patient’s seizures and potential neural damage in the brain and spinal cord.
So far the drug candidate has completed phase 1 development in the United States under and active Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
VistaGen Therapeutics believes that safety results from the completed phase 1 program has the potential to position the candidate for phase 2 development for both neuropathic pain and depression.
For more information, visit www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Recent market research estimates that more than 1.5 billion people worldwide are afflicted with neuropathic pain, costing the U.S. public health system alone between $560 billion – $635 billion annually, according to the American Academy of Pain Medicine.
Small-cap company VistaGen Therapeutics’ lead small molecule drug candidate, AV-101, is being developed in the United States for the treatment of neuropathic pain. AV-101 is also being developed for additional indications, such as depression and other neurological indications.
To-date, the company has been awarded more than $8.8 million from the National Institute of Health for the development of this treatment.
In preclinical studies, AV-101 demonstrated positive levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier, and preferential conversion into 7-CKYNA at the site of the patient’s seizures and potential neural damage in the brain and spinal cord.
So far the drug candidate has completed phase 1 development in the United States under and active Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
VistaGen Therapeutics believes that safety results from the completed phase 1 program has the potential to position the candidate for phase 2 development for both neuropathic pain and depression.
For more information, visit www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, October 30, 2013
Cardium Therapeutics, Inc. (CXM) Enhances Well-being with Family of Nutraceutical Supplement Products
Cardium Therapeutics is an asset-based health sciences and regenerative medicine company that focuses on new and innovative bio-medical product opportunities and businesses that have potential to address significant unmet medical needs. The company seeks to acquire, develop and leverage multiple medical opportunities and use its skills in late-stage product development to foster multiple diverse channels of profitability and bring promising bio-medical solutions to market. To achieve those goals, Cardium looks for possible acquisition targets that exhibit strong potential in pathways to commercialization, partnering, or alternative economic monetizations. The company’s target prospects and current asset holdings of bio-medical product and technologies range from new innovations to well-established brands.
Among other opportunities in its diverse portfolio, Cardium holds what is a recent but perhaps surprising acquisition: To Go Brands, a healthy nutraceutical supplement business, which Cardium acquired a year ago in October 2012. This company sports a wide range of healthy lifestyle products that are well-established in the marketplace and will continue to serve as dependable revenue generators for long-term stability.
To Go Brands develops, markets, and sells a portfolio of more than 25 products, including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. This product line features 100 percent natural, antioxidant-rich drink mixes with organic ingredients, available in mix packages, sticks packs, and as capsule-based dietary supplements. The products function to fostering healthy lifestyles for prevention of or safeguarding against serious health conditions such as diabetes. In the United States alone, more than 25 million people are estimated to have diabetes, with 27 percent of that population remaining undiagnosed.
To Go Brands’ products have an established retail selling presence, as they are currently offered in more than 10,000 locations belonging to leading retail vendors including Whole Foods, CVS, Kroger, GNC, Jewel-Osco, Ralph’s Supermarkets, Meijr, and the Vitamin Shoppe. They are also available for purchase on To Go Brands’ online marketplace as well.
To Go Brands is part of Cardium’s three-part medical opportunities portfolio, which also includes the Tissue Repair Company and Cardium Biologics. These two companies are the developers of Excellagen and Generx, products that enable wound healing and management and treatment of cardiovascular indicators, respectively.
For more information visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Among other opportunities in its diverse portfolio, Cardium holds what is a recent but perhaps surprising acquisition: To Go Brands, a healthy nutraceutical supplement business, which Cardium acquired a year ago in October 2012. This company sports a wide range of healthy lifestyle products that are well-established in the marketplace and will continue to serve as dependable revenue generators for long-term stability.
To Go Brands develops, markets, and sells a portfolio of more than 25 products, including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. This product line features 100 percent natural, antioxidant-rich drink mixes with organic ingredients, available in mix packages, sticks packs, and as capsule-based dietary supplements. The products function to fostering healthy lifestyles for prevention of or safeguarding against serious health conditions such as diabetes. In the United States alone, more than 25 million people are estimated to have diabetes, with 27 percent of that population remaining undiagnosed.
To Go Brands’ products have an established retail selling presence, as they are currently offered in more than 10,000 locations belonging to leading retail vendors including Whole Foods, CVS, Kroger, GNC, Jewel-Osco, Ralph’s Supermarkets, Meijr, and the Vitamin Shoppe. They are also available for purchase on To Go Brands’ online marketplace as well.
To Go Brands is part of Cardium’s three-part medical opportunities portfolio, which also includes the Tissue Repair Company and Cardium Biologics. These two companies are the developers of Excellagen and Generx, products that enable wound healing and management and treatment of cardiovascular indicators, respectively.
For more information visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, October 29, 2013
Galena Biopharma, Inc. (GALE) CEO Dr. Mark Ahn is Well-Versed in Biopharm, Corporate Management
Galena Biopharma is a biopharmaceutical company focused on developing and commercializing treatments to address major unmet medical needs in the field of oncology. As GALE works to expand its drug candidate portfolio, the company’s stated mission is to accelerate value for both patients and company shareholders, a goal that requires support and guidance from an experienced and aggressive management team.
Leading the company’s corporate initiatives is Mark J. Ahn, Ph.D., who has more than 20 years of experience in the biopharmaceutical industry. Dr. Ahn has served as GALE’s president and CEO since March 2011, and has also served as a director of the company since 2007.
Prior to joining GALE, Dr. Ahn was principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and associate professor of Global Management at Atkinson Graduate School of Management, Willamette University. He also previously served as professor and chair of Science & Technology Management for Victoria University at Wellington, New Zealand.
Dr. Ahn was also founder and was previously the president and CEO of Hana Biosciences following his employment as vice president of Hematology and corporate officer at Genentech, Inc. In addition, he has held positions of increasing responsibility at Amgen (AMGN) and Bristol-Myers Squibb (BMY).
Dr. Ahn has authored more than 50 peer reviewed journal articles and books, and serves on public and venture capital-backed board of directors for Access Pharmaceuticals, Mesynthes, and ScribesSTAT. He received a BA and an MBA from Chaminade University, as well as an MA from Victoria University. Furthermore, Dr. Ahn was a graduate fellow in economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.
For more information visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Leading the company’s corporate initiatives is Mark J. Ahn, Ph.D., who has more than 20 years of experience in the biopharmaceutical industry. Dr. Ahn has served as GALE’s president and CEO since March 2011, and has also served as a director of the company since 2007.
Prior to joining GALE, Dr. Ahn was principal at Pukana Partners, Ltd., which provides strategic consulting to life science companies; and associate professor of Global Management at Atkinson Graduate School of Management, Willamette University. He also previously served as professor and chair of Science & Technology Management for Victoria University at Wellington, New Zealand.
Dr. Ahn was also founder and was previously the president and CEO of Hana Biosciences following his employment as vice president of Hematology and corporate officer at Genentech, Inc. In addition, he has held positions of increasing responsibility at Amgen (AMGN) and Bristol-Myers Squibb (BMY).
Dr. Ahn has authored more than 50 peer reviewed journal articles and books, and serves on public and venture capital-backed board of directors for Access Pharmaceuticals, Mesynthes, and ScribesSTAT. He received a BA and an MBA from Chaminade University, as well as an MA from Victoria University. Furthermore, Dr. Ahn was a graduate fellow in economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.
For more information visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Marathon Patent Group, Inc. (MARA) is “One to Watch”
Marathon Patent Group services a broad array of patent owners to help them license their portfolios, from individual inventors up to Fortune 500 companies. Marathon, via its operating subsidiaries, also acquires or invests in promising patent assets/rights with the ultimate objective of generating licensing revenues.
Since its inception, the company has been quite busy sourcing top-shelf patent portfolios via channels. An example would be their tight-knit working relationship with one of the global leaders in full-service patent monetization, IPNav, and its CEO, Erich Spangenberg, who is part of that relationship stretching back to 1998.
The experienced licensing team at MARA has devised an extremely rigorous vetting process involving collaborative due diligence, which also relies heavily on the established licensing strategies developed by IPNav – strategies that have helped IPNav pull down some $620M in settlements over the last decade alone.
MARA’s current patent load out, amassed either via direct upfront payment or through participation in revenue generation for the patent sellers, currently tips the scales at some 35 U.S. patents and 64 international patents. Just last week (Oct 22) MARA reaffirmed its patent licensing prowess to markets yet again with the acquisition of a portfolio of four U.S. patents in the process automation (production) and enterprise resource planning area, dealing with the implementation of adaptive learning methods. This marks the third portfolio the company (or one of its operating subsidiaries) has snapped up in just the four weeks preceding the announcement itself.
Marathon is a lean, mean and appropriately aggressive outfit that has a solid balance sheet and no debt. With Q2 figures on display, MARA is reporting the first real quarter during which the company has reported significant licensing and settlement revenues. This profile provides investors with a clear glimpse of MARA’s financial status via 33 active lawsuits and over 42 different defendants (reported Aug 15). With gross revenue that broke $1.5M on settlement and licensing proceeds, it should be obvious where this company is headed. In fact, MARA pushing numbers like that in their first real quarter of patent enforcement activity should be a major signal to investors that both the strength of their patents and the veracity of their enforcement capabilities are something to keep a close eye on in coming months. The sheer speed with which Marathon has managed to drop the hammer on monetization of their portfolio says it all.
Earlier in August (Aug 2) the company’s newly launched campaign for wholly-owned subsidiary Relay IP Inc., resulted in filing of a patent infringement lawsuit against leading New York metropolitan area telecommunications and media company, Cablevision, over their Internet protocol network multicasting territory (USPTO #5,331,637 – multicast routing using core-based trees). This was just shortly after the company’s initial Relay IP victory in July, a short three months into the launch of the new licensing campaign, as Relay IP successfully entered into a settlement and license agreement with a top tech firm over the Relay IP patent. Another patent infringement lawsuit in Relay IP, this time against 10 major named defendants and filed in June (including big names like The Nasdaq OMX Group, Inc. and BATS Trading Inc.) offers yet more tangible evidence of the strength of MARA’s position. Relay IP territory is essentially IP multicast and this patent position has huge coverage in the growing world of IPTV applications like distance learning or televised company meetings. It is also the most widely used protocol in Protocol Independent Multicast or PIM.
Earlier in the year (May 30), MARA acquired three U.S. and ten international patents from undisputed global electronics and electrical engineering heavyweight, Siemens, via their wholly-owned Bismarck IP subsidiary. The three patents relate to enhancement features and performance technologies in switching communication terminal equipment and Private Branch Exchanges (PBXs). Trusted ally IPNav has already been tapped to help MARA monetize this fertile patent territory and the strategic might of the company’s overall patent position should be self-evident when also taking into account their Sampo IP and Cyberfone assets (covering areas of distributed application communications and menu/form-driven data transactions respectively). IPNav’s sophisticated toolset includes their custom IPNav Analyzer, a patent analytics and market analysis engine, as well as their transaction and licensing agreement database which spans multiple industries and technology areas.
Founder and CEO of MARA, Doug Croxall, marveling at the robust and highly scalable IP monetization platform the company has put together, emphasized the 6.4M in cash the company had on hand as of late June. Add to that the lack of debt on their balance sheet, and these leading indicators reveal how spry MARA will be in terms of portfolio expansion and monetization this year and on into 2014.
A diverse yet strategically relevant portfolio that is constantly growing, and a close partnership with patent monetization juggernaut IPNav spell out tremendous upside in a world increasingly dependent on distributed information and communication technologies. Marathon’s modular approach to territory acquisition via outright purchase or partnering with the patent holder, ultimately resulting in actively managed patent licensing campaigns, is a brilliant model, and this Alexandria, Virginia-based company has the executive muscle to support their inevitable growth dynamics as well. Croxall himself cut his teeth in the industry with powerhouses like KPMG and Motorola, then moved on to head up Firepond, where he achieved some $90M in patent licensing revenues from 2004 to 2009 before going on to found his own successful, privately-owned patent holding company, LVL Patent Group.
The company’s Sampo IP assets (Sampo IP, LLC) saw the first and second settlement agreements landed within four months of the kick off of their licensing campaign in March, and these assets in particular represent a rapidly evolving area for MARA where ongoing infringement continues on the centrifugal communication and collaboration method patents. These patents cover facilitation of communication between members of a distributed discussion group using communication devices and a central agent.
The Cyberfone assets (CyberFone Systems, LLC) cover a range of certain transactional data processing, telecommunications, network and database inventions, and includes financial transactions and enforcement which is open-ended against such high-profile named defendants as Alcatel-Lucent, Mitsubishi, Toshiba, and UPS. The settlement achieved with Denon Electronics, LLC in June of this year on the Cyberfone assets illustrated how secure the company’s patent position is and the truly foundational digital communications and data transaction processing areas covered by this portfolio for the finance, telecom, and wireless sectors alone are enormous.
Learn more about Marathon Patent Group, Inc. at www.MarathonPG.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Since its inception, the company has been quite busy sourcing top-shelf patent portfolios via channels. An example would be their tight-knit working relationship with one of the global leaders in full-service patent monetization, IPNav, and its CEO, Erich Spangenberg, who is part of that relationship stretching back to 1998.
The experienced licensing team at MARA has devised an extremely rigorous vetting process involving collaborative due diligence, which also relies heavily on the established licensing strategies developed by IPNav – strategies that have helped IPNav pull down some $620M in settlements over the last decade alone.
MARA’s current patent load out, amassed either via direct upfront payment or through participation in revenue generation for the patent sellers, currently tips the scales at some 35 U.S. patents and 64 international patents. Just last week (Oct 22) MARA reaffirmed its patent licensing prowess to markets yet again with the acquisition of a portfolio of four U.S. patents in the process automation (production) and enterprise resource planning area, dealing with the implementation of adaptive learning methods. This marks the third portfolio the company (or one of its operating subsidiaries) has snapped up in just the four weeks preceding the announcement itself.
Marathon is a lean, mean and appropriately aggressive outfit that has a solid balance sheet and no debt. With Q2 figures on display, MARA is reporting the first real quarter during which the company has reported significant licensing and settlement revenues. This profile provides investors with a clear glimpse of MARA’s financial status via 33 active lawsuits and over 42 different defendants (reported Aug 15). With gross revenue that broke $1.5M on settlement and licensing proceeds, it should be obvious where this company is headed. In fact, MARA pushing numbers like that in their first real quarter of patent enforcement activity should be a major signal to investors that both the strength of their patents and the veracity of their enforcement capabilities are something to keep a close eye on in coming months. The sheer speed with which Marathon has managed to drop the hammer on monetization of their portfolio says it all.
Earlier in August (Aug 2) the company’s newly launched campaign for wholly-owned subsidiary Relay IP Inc., resulted in filing of a patent infringement lawsuit against leading New York metropolitan area telecommunications and media company, Cablevision, over their Internet protocol network multicasting territory (USPTO #5,331,637 – multicast routing using core-based trees). This was just shortly after the company’s initial Relay IP victory in July, a short three months into the launch of the new licensing campaign, as Relay IP successfully entered into a settlement and license agreement with a top tech firm over the Relay IP patent. Another patent infringement lawsuit in Relay IP, this time against 10 major named defendants and filed in June (including big names like The Nasdaq OMX Group, Inc. and BATS Trading Inc.) offers yet more tangible evidence of the strength of MARA’s position. Relay IP territory is essentially IP multicast and this patent position has huge coverage in the growing world of IPTV applications like distance learning or televised company meetings. It is also the most widely used protocol in Protocol Independent Multicast or PIM.
Earlier in the year (May 30), MARA acquired three U.S. and ten international patents from undisputed global electronics and electrical engineering heavyweight, Siemens, via their wholly-owned Bismarck IP subsidiary. The three patents relate to enhancement features and performance technologies in switching communication terminal equipment and Private Branch Exchanges (PBXs). Trusted ally IPNav has already been tapped to help MARA monetize this fertile patent territory and the strategic might of the company’s overall patent position should be self-evident when also taking into account their Sampo IP and Cyberfone assets (covering areas of distributed application communications and menu/form-driven data transactions respectively). IPNav’s sophisticated toolset includes their custom IPNav Analyzer, a patent analytics and market analysis engine, as well as their transaction and licensing agreement database which spans multiple industries and technology areas.
Founder and CEO of MARA, Doug Croxall, marveling at the robust and highly scalable IP monetization platform the company has put together, emphasized the 6.4M in cash the company had on hand as of late June. Add to that the lack of debt on their balance sheet, and these leading indicators reveal how spry MARA will be in terms of portfolio expansion and monetization this year and on into 2014.
A diverse yet strategically relevant portfolio that is constantly growing, and a close partnership with patent monetization juggernaut IPNav spell out tremendous upside in a world increasingly dependent on distributed information and communication technologies. Marathon’s modular approach to territory acquisition via outright purchase or partnering with the patent holder, ultimately resulting in actively managed patent licensing campaigns, is a brilliant model, and this Alexandria, Virginia-based company has the executive muscle to support their inevitable growth dynamics as well. Croxall himself cut his teeth in the industry with powerhouses like KPMG and Motorola, then moved on to head up Firepond, where he achieved some $90M in patent licensing revenues from 2004 to 2009 before going on to found his own successful, privately-owned patent holding company, LVL Patent Group.
The company’s Sampo IP assets (Sampo IP, LLC) saw the first and second settlement agreements landed within four months of the kick off of their licensing campaign in March, and these assets in particular represent a rapidly evolving area for MARA where ongoing infringement continues on the centrifugal communication and collaboration method patents. These patents cover facilitation of communication between members of a distributed discussion group using communication devices and a central agent.
The Cyberfone assets (CyberFone Systems, LLC) cover a range of certain transactional data processing, telecommunications, network and database inventions, and includes financial transactions and enforcement which is open-ended against such high-profile named defendants as Alcatel-Lucent, Mitsubishi, Toshiba, and UPS. The settlement achieved with Denon Electronics, LLC in June of this year on the Cyberfone assets illustrated how secure the company’s patent position is and the truly foundational digital communications and data transaction processing areas covered by this portfolio for the finance, telecom, and wireless sectors alone are enormous.
Learn more about Marathon Patent Group, Inc. at www.MarathonPG.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Dot Hill (HILL) AssuredSAN Pro 5000 Selected by C7 Data Centers for Private Cloud Solution
Dot Hill Systems Corp. (HILL), a prominent supplier of SAN storage products, announced today that its AssuredSAN Pro 5000 Series 100 terabyte offering has been selected by C7 Data Centers, a leader in outsourced IT solutions, for incorporation into C7’s new private cloud configuration. Dot Hill’s AssuredSAN Pro 5000 Series features real-time automated tiering for single tenant private cloud solutions, making it an ideal selection for C7’s new offering which provides affordable cloud-based redundancy in both physical and virtual production environments.
“Many companies are looking at cloud implementations to grow IT resources without increasing support and hardware costs,” said Jim Jonez, senior director of marketing, Dot Hill. “C7 Data Centers and Dot Hill are working together to provide a responsive, reliable, and cost-effective infrastructure. The Dot Hill AssuredSAN Pro 5000 Series allows cloud customers to increase capacity without having to purchase additional licenses, providing savings to their bottom line.”
“We’re confident that in our FuseApp Private Cloud and Private Cloud Suite solutions we’ve found the right mix of technologies to provide a robust, affordable failover solution for physical and virtual production environments that is easy to scale,” said Wes Swenson, CEO, C7 Data Centers. “The Dot Hill AssuredSAN Pro 5000 Series provides 99.999 percent availability and real-time tiering — features that meet the performance requirements of a production site.”
The AssuredSAN Pro 5000 Series has built-in intelligence that automatically adjusts to data access needs without human involvement or policy modification. The AssuredSAN Pro Series, with RealStor™ software raises the bar on tiered storage, above other automated off-hours batch migration tiered storage systems, and up to a new level of autonomic, real-time data tiering.
The AssuredSAN Pro 5000 Series is a cutting edge, high-performance integrated storage array that consistently delivers faster access to up-to-date data with built-in, real-time autonomic tiered storage and virtualization. This highly available and reliable solution immediately detects priorities for data access to optimize the delivery of high demand data in real time. Faster I/O is achieved in part through real-time automated data tiering, which prioritizes data files, volumes or blocks between tiered storage using built-in analysis and data scoring
For further information, please visit www.dothill.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Many companies are looking at cloud implementations to grow IT resources without increasing support and hardware costs,” said Jim Jonez, senior director of marketing, Dot Hill. “C7 Data Centers and Dot Hill are working together to provide a responsive, reliable, and cost-effective infrastructure. The Dot Hill AssuredSAN Pro 5000 Series allows cloud customers to increase capacity without having to purchase additional licenses, providing savings to their bottom line.”
“We’re confident that in our FuseApp Private Cloud and Private Cloud Suite solutions we’ve found the right mix of technologies to provide a robust, affordable failover solution for physical and virtual production environments that is easy to scale,” said Wes Swenson, CEO, C7 Data Centers. “The Dot Hill AssuredSAN Pro 5000 Series provides 99.999 percent availability and real-time tiering — features that meet the performance requirements of a production site.”
The AssuredSAN Pro 5000 Series has built-in intelligence that automatically adjusts to data access needs without human involvement or policy modification. The AssuredSAN Pro Series, with RealStor™ software raises the bar on tiered storage, above other automated off-hours batch migration tiered storage systems, and up to a new level of autonomic, real-time data tiering.
The AssuredSAN Pro 5000 Series is a cutting edge, high-performance integrated storage array that consistently delivers faster access to up-to-date data with built-in, real-time autonomic tiered storage and virtualization. This highly available and reliable solution immediately detects priorities for data access to optimize the delivery of high demand data in real time. Faster I/O is achieved in part through real-time automated data tiering, which prioritizes data files, volumes or blocks between tiered storage using built-in analysis and data scoring
For further information, please visit www.dothill.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CytRx Corp. (CYTR) Reports Q3 2013 Financial Results and Clinical Update
CytRx Corp. today announced its financial results and clinical update for the quarter ended September 30, 2013.
“Our achievements during the third quarter and recent weeks position CytRx to make significant progress and create shareholder value for the remainder of 2013 and well into 2014,” Steven A. Kriegsman, CYTR president and CEO stated in the press release. “With our cash position bolstered by a recent equity offering that netted approximately $24.1 million, we have the resources to continue a robust program of clinical trials with aldoxorubicin in multiple oncology indications. Later this week, we will be presenting further impressive preliminary results from our global Phase 2b clinical trial in first-line soft tissue sarcoma at the Connective Tissue Oncology Society Annual Meeting in New York.
“In the third quarter, we were excited to announce that aldoxorubicin significantly increased survival rates in mice transplanted with human glioblastoma cells in a confirmatory study, and demonstrated the ability in that study to cross the blood-brain barrier and induce key biomarkers that lead to glioblastoma tumor cell death. Glioblastoma is a deadly form of brain cancer, and we plan to initiate a Phase 2 trial later this year in patients with advanced, relapsed glioblastoma, and a Phase 2 trial in Kaposi’s sarcoma, a common HIV-associated tumor,” continued Mr. Kriegsman. “Finally, we expect to commence a global Phase 3 pivotal trial in the first quarter of 2014 to evaluate aldoxorubicin as a treatment for patients with second-line soft tissue sarcomas that have progressed following prior treatment with chemotherapy. That trial is being conducted under a special protocol assessment with progression-free survival as the primary endpoint.”
CYTR reported a net loss of $10.0 million for Q3 2013, or $0.33 per diluted share, compared with a net income of $1.6 million, or $0.07 per diluted share, for Q3 2012. CYTR said the difference was strongly attributable to its warrant derivative losses, which were a loss of $4.0 million compared with a non-cash gain of $6.4 million in warrant derivative losses in Q3 2012.
Research and development expenses were reported as $4.0 million for Q3 2013, including $3.3 million for development of one of CYTR’s chemotherapeutic agents, Aldoxorubicin. General and administrative expenses were $2.0 million for Q3 2013, compared to $1.7 million for the same period in 2012.
CYTR also reported cash, cash equivalents, and short-term investments of $23.0 million and no debt this quarter. Just before the closing of the quarter, it completed an underwritten public offering of common stock, generating net proceeds of around $24.1 million.
The company also provided the following clinical update details:
Recent Clinical Highlights
• July – reported highly favorable data from a human model of glioblastoma implanted in animals and treated with aldoxorubicin, including statistically significant efficacy and prolonged survival.
• September – announced preliminary data from the global Phase 2b soft tissue sarcoma trial showing patients treated with aldoxorubicin had an Overall Response Rate (ORR) of 22%, whereas those administered the widely used chemotherapeutic agent doxorubicin had an ORR of 0%.
Upcoming Milestones
• 4Q13 – initiate a Phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma. Study site participants include The John Wayne Cancer Center in Santa Monica, Calif., the City of Hope in Duarte, Calif. and the LSU Health Science Center in New Orleans.
• 4Q13 – initiate a Phase 2 trial evaluating the preliminary efficacy of aldoxorubicin in treating AIDS-related Kaposi’s sarcoma; this trial will enroll up to 30 patients at the LSU Health Science Center.
• December 2013 – report top-line progression-free survival results from the global Phase 2b trial comparing the efficacy and safety of aldoxorubicin and doxorubicin as a first-line treatment for patients with soft tissue sarcoma.
• 1Q14 – initiate a global Phase 3 pivotal trial with aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma who have failed chemotherapy under a special protocol assessment.
• Ongoing – work to expand the oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents.
For more information, visit: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Our achievements during the third quarter and recent weeks position CytRx to make significant progress and create shareholder value for the remainder of 2013 and well into 2014,” Steven A. Kriegsman, CYTR president and CEO stated in the press release. “With our cash position bolstered by a recent equity offering that netted approximately $24.1 million, we have the resources to continue a robust program of clinical trials with aldoxorubicin in multiple oncology indications. Later this week, we will be presenting further impressive preliminary results from our global Phase 2b clinical trial in first-line soft tissue sarcoma at the Connective Tissue Oncology Society Annual Meeting in New York.
“In the third quarter, we were excited to announce that aldoxorubicin significantly increased survival rates in mice transplanted with human glioblastoma cells in a confirmatory study, and demonstrated the ability in that study to cross the blood-brain barrier and induce key biomarkers that lead to glioblastoma tumor cell death. Glioblastoma is a deadly form of brain cancer, and we plan to initiate a Phase 2 trial later this year in patients with advanced, relapsed glioblastoma, and a Phase 2 trial in Kaposi’s sarcoma, a common HIV-associated tumor,” continued Mr. Kriegsman. “Finally, we expect to commence a global Phase 3 pivotal trial in the first quarter of 2014 to evaluate aldoxorubicin as a treatment for patients with second-line soft tissue sarcomas that have progressed following prior treatment with chemotherapy. That trial is being conducted under a special protocol assessment with progression-free survival as the primary endpoint.”
CYTR reported a net loss of $10.0 million for Q3 2013, or $0.33 per diluted share, compared with a net income of $1.6 million, or $0.07 per diluted share, for Q3 2012. CYTR said the difference was strongly attributable to its warrant derivative losses, which were a loss of $4.0 million compared with a non-cash gain of $6.4 million in warrant derivative losses in Q3 2012.
Research and development expenses were reported as $4.0 million for Q3 2013, including $3.3 million for development of one of CYTR’s chemotherapeutic agents, Aldoxorubicin. General and administrative expenses were $2.0 million for Q3 2013, compared to $1.7 million for the same period in 2012.
CYTR also reported cash, cash equivalents, and short-term investments of $23.0 million and no debt this quarter. Just before the closing of the quarter, it completed an underwritten public offering of common stock, generating net proceeds of around $24.1 million.
The company also provided the following clinical update details:
Recent Clinical Highlights
• July – reported highly favorable data from a human model of glioblastoma implanted in animals and treated with aldoxorubicin, including statistically significant efficacy and prolonged survival.
• September – announced preliminary data from the global Phase 2b soft tissue sarcoma trial showing patients treated with aldoxorubicin had an Overall Response Rate (ORR) of 22%, whereas those administered the widely used chemotherapeutic agent doxorubicin had an ORR of 0%.
Upcoming Milestones
• 4Q13 – initiate a Phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma. Study site participants include The John Wayne Cancer Center in Santa Monica, Calif., the City of Hope in Duarte, Calif. and the LSU Health Science Center in New Orleans.
• 4Q13 – initiate a Phase 2 trial evaluating the preliminary efficacy of aldoxorubicin in treating AIDS-related Kaposi’s sarcoma; this trial will enroll up to 30 patients at the LSU Health Science Center.
• December 2013 – report top-line progression-free survival results from the global Phase 2b trial comparing the efficacy and safety of aldoxorubicin and doxorubicin as a first-line treatment for patients with soft tissue sarcoma.
• 1Q14 – initiate a global Phase 3 pivotal trial with aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma who have failed chemotherapy under a special protocol assessment.
• Ongoing – work to expand the oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents.
For more information, visit: www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Chanticleer Holdings (HOTR) Announces Key Appointments in Corporate Structure for American Roadside Burgers
Chanticleer Holdings, owner and operator of Hooters® branded restaurants in emerging international markets, today said it has appointed Richard Adams, former regional vice president of Bojangles’ Restaurants, Inc., as president and CEO of HOTR’s Charlotte, North Carolina-based subsidiary, American Roadside Burgers. This appointment became effective October 28, 2013. HOTR also appointed Thomas Lewison as a company strategic advisor.
“We are pleased to welcome Rich to lead the management and development of our newest subsidiary, American Roadside Burgers. With his extensive experience in the restaurant industry, Rich is an excellent addition to the team, especially at this exciting time in our company’s development,” Mike Pruitt, chairman and CEO of HOTR, stated in the news release. “Tom’s vast industry knowledge and experience will help Chanticleer Holdings move towards further expansion for all our subsidiaries and evaluation of new opportunities.”
Adams brings more than 35 years of experience in the restaurant industry to his new appointment at American Roadside Burgers. In his 10 years at Bojangles’ Restaurants, he served in many positions including director of training; vice president of franchise operations; and for the past five years was regional vice president of company operations where he led Bojangles’ core market in Charlotte, NC. Prior to his time at Bojangles’ Restaurants, he worked as a regional vice president for CKE Restaurants and later an area vice president for a Burger King franchisee in Louisiana, where he led 100 restaurants.
“I am excited about the opportunity to join American Roadside Burgers at this time as Chanticleer Holdings advances its subsidiaries in the United States and all over the world,” Adams stated.
Lewison, who is a franchisee of 15 Qdoba Mexican Grill locations, was a board member of American Roadside Burgers. In addition to his restaurant holdings, he has ownership in 20/20 Restaurant Group, a consulting service to the restaurant industry. Prior to his involvement in these enterprises, Lewison advanced through the ranks at CKE Restaurants and eventually moved to Hardee’s Food Systems as executive vice president after CKE Restaurants acquired that company in 1997. After being with CKE Restaurants for 22 years, he became president and chief operating officer for Bojangles’ Restaurants in 2001. In that capacity, Lewison turned around Bojangles’ Restaurants’ company performance with implementation of a strategic plan he crafted. Consequently shareholders in Bojangles’ Restaurants saw an above average return on their investment when the company was sold in 2007.
“There are so many great operators out there without capital, and so much capital that can’t operate a restaurant,” says Tom Lewison. “That’s why I love Mike Pruitt’s model. It understands the balance.”
More information regarding HOTR and its current initiatives can be found at: www.chanticleerholdings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are pleased to welcome Rich to lead the management and development of our newest subsidiary, American Roadside Burgers. With his extensive experience in the restaurant industry, Rich is an excellent addition to the team, especially at this exciting time in our company’s development,” Mike Pruitt, chairman and CEO of HOTR, stated in the news release. “Tom’s vast industry knowledge and experience will help Chanticleer Holdings move towards further expansion for all our subsidiaries and evaluation of new opportunities.”
Adams brings more than 35 years of experience in the restaurant industry to his new appointment at American Roadside Burgers. In his 10 years at Bojangles’ Restaurants, he served in many positions including director of training; vice president of franchise operations; and for the past five years was regional vice president of company operations where he led Bojangles’ core market in Charlotte, NC. Prior to his time at Bojangles’ Restaurants, he worked as a regional vice president for CKE Restaurants and later an area vice president for a Burger King franchisee in Louisiana, where he led 100 restaurants.
“I am excited about the opportunity to join American Roadside Burgers at this time as Chanticleer Holdings advances its subsidiaries in the United States and all over the world,” Adams stated.
Lewison, who is a franchisee of 15 Qdoba Mexican Grill locations, was a board member of American Roadside Burgers. In addition to his restaurant holdings, he has ownership in 20/20 Restaurant Group, a consulting service to the restaurant industry. Prior to his involvement in these enterprises, Lewison advanced through the ranks at CKE Restaurants and eventually moved to Hardee’s Food Systems as executive vice president after CKE Restaurants acquired that company in 1997. After being with CKE Restaurants for 22 years, he became president and chief operating officer for Bojangles’ Restaurants in 2001. In that capacity, Lewison turned around Bojangles’ Restaurants’ company performance with implementation of a strategic plan he crafted. Consequently shareholders in Bojangles’ Restaurants saw an above average return on their investment when the company was sold in 2007.
“There are so many great operators out there without capital, and so much capital that can’t operate a restaurant,” says Tom Lewison. “That’s why I love Mike Pruitt’s model. It understands the balance.”
More information regarding HOTR and its current initiatives can be found at: www.chanticleerholdings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MRI Interventions, Inc. (MRIC) Reports Positive Data of Asleep DBS with ClearPoint® System
MRI Interventions, developer of innovative platforms for performing minimally invasive surgical procedures in the brain and heart, has reported that data from the use of the company’s ClearPoint(R) Neuro Intervention System in “asleep” deep brain stimulation (DBS) surgery were recently presented during the 2013 Annual Meeting of the Congress of Neurological Surgeons (CNS) in San Francisco.
The ClearPoint System is a navigation platform designed to provide surgeons with real-time, direct visualization during minimally invasive neurosurgical procedures. Dr. Paul Larson, neurosurgeon at the University of California, San Francisco (UCSF), presented at the meeting the accuracy results from a prospective study of 60 patients who underwent asleep DBS with the ClearPoint System.
“Almost every electrode was placed with a single pass to the brain,” Dr. Larson stated after his presentation, “meaning we hit the target the first time in each of those cases. More importantly, we hit the correct target based on the fact that no patients have returned for repositioning. We were able to do this through real-time image guidance enabled by ClearPoint.”
In addition, Dr. Fiona Gupta, neurologist at Hackensack University Medical Center (HUMC), presented clinical outcomes of 11 patients who underwent asleep DBS with the ClearPoint System at HUMC.
“We’ve been very impressed with the outcomes we have seen so far,” said Dr. Gupta. “My patients have had dramatic improvement in their movement scores. Many of these patients would not have had the awake surgery, so these results were made possible by iMRI asleep DBS.”
Lastly, Dr. Jill Ostrem, neurologist at UCSF, presented preliminary data regarding outcomes with asleep DBS from a UCSF clinical study.
“While our data is preliminary at this point, I can say that the patients we’ve assessed so far are doing very well,” Dr. Ostrem stated. “Initial clinical outcomes are in line with outcomes in conventional awake procedures, which is exactly what we want to see at this point.”
For more information please visit www.mriinterventions.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The ClearPoint System is a navigation platform designed to provide surgeons with real-time, direct visualization during minimally invasive neurosurgical procedures. Dr. Paul Larson, neurosurgeon at the University of California, San Francisco (UCSF), presented at the meeting the accuracy results from a prospective study of 60 patients who underwent asleep DBS with the ClearPoint System.
“Almost every electrode was placed with a single pass to the brain,” Dr. Larson stated after his presentation, “meaning we hit the target the first time in each of those cases. More importantly, we hit the correct target based on the fact that no patients have returned for repositioning. We were able to do this through real-time image guidance enabled by ClearPoint.”
In addition, Dr. Fiona Gupta, neurologist at Hackensack University Medical Center (HUMC), presented clinical outcomes of 11 patients who underwent asleep DBS with the ClearPoint System at HUMC.
“We’ve been very impressed with the outcomes we have seen so far,” said Dr. Gupta. “My patients have had dramatic improvement in their movement scores. Many of these patients would not have had the awake surgery, so these results were made possible by iMRI asleep DBS.”
Lastly, Dr. Jill Ostrem, neurologist at UCSF, presented preliminary data regarding outcomes with asleep DBS from a UCSF clinical study.
“While our data is preliminary at this point, I can say that the patients we’ve assessed so far are doing very well,” Dr. Ostrem stated. “Initial clinical outcomes are in line with outcomes in conventional awake procedures, which is exactly what we want to see at this point.”
For more information please visit www.mriinterventions.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, October 28, 2013
3 Reasons to Buy ForceField Energy, Inc. (FNRG)
Several years ago, renewable energy was one of the hottest sectors in the market. The companies in that niche seemed to be trading at higher highs every week. Eventually the action cooled off and share prices returned to normal valuations. But over the past few months it appears that investor enthusiasm for these stocks is back. One stock that appears poised for significant growth is ForceField Energy. Below are 3 reasons why investors should consider investing in the company.
Company Profile
ForceField Energy primarily operates in two distinct segments of renewable energy; LED lighting and waste heat recovery through its majority ownership of TransPacific Energy (“TPE”) a U.S.- based renewable energy provider that uses “waste heat” from various manufacturing and other sources to provide clean electricity. These are among the fastest growing areas of the worldwide renewable energy market with the total expected market to hit $500 billion by 2017.
Reason #1 – Recent Technical Strength
ForceField Energy has taken off in the past month as investors appear to have a better understanding of the company’s business and prospects. Over the past 30 days, shares of the company are up approximately 8%. The chart below shows the nice move that investors have enjoyed.
FNRG 1
In comparison, investors can look at the SPDR S&P 500 ETF Trust (SPY) to see how the broader market has performed. Over the same 30 day period, the overall market is only up approximately 3% as shown by the chart below.
FNRG 2
ForceField’s chart appears to be headed even higher given that the news highs have come on high volume trading days. Although it can be risky to buy at a new high, given the potential that the company has, investors may not want to miss the opportunity.
Reason #2 – LED Market Opportunity
Another part of the company’s business that should excite investors is the company’s participating in the LED market. FNRG recently has the exclusive North American, Latin American and European rights; and rest of world rights on a non-exclusive basis from a highly regarded LED manufacturer to distribute high-performance light emitting diode (LED) lighting fixtures used in many diverse applications. LED technology is expected to replace incandescent and fluorescent fixtures as it offers longer lifecycles, cost savings, and reduced energy consumption. LED technology is expected to have an even a stronger impact in the current economic environment where companies are aggressively seeking reductions in operating costs. LED lends itself well to these initiatives as both an immediate and long term solution.
The U.S. Department of Energy estimates that there are over 2.5 billion fixtures in commercial and industrial properties throughout the United States. The replacement cost of these fixtures and others worldwide could possibly exceed one trillion dollars. Given ForceField’s desirable position in this market, revenues could soar.
Reason #3 – NASDAQ Listing Offers Investors More Liquidity
On October 17th, ForceField Energy shares began trading on the NASDAQ. The listing should allow the company to gain more name recognition with traders and investors as the move provides greater liquidity and increased exposure to investment firms and money managers across the world. Given the company’s position within the renewable energy space, it is likely that momentum traders could soon pile in and give retail investors a reason to celebrate.
Risks
Although it appears ForceField has an incredible amount of potential, investors should know that with all micro-cap companies, especially in a risky industry such as renewable energy, raising cash is always challenging. Based on the company’s current balance sheet, relatively modest share count outstanding (16.3 million shares) and the Company’s demonstrated ability to raise capital on favorable terms ($6.0+ million over the past three years) with minimal dilution, it appears that Company has the ability to fund its operation in 2014 and going forward. In order to fully achieve their business plan it is possible that the Company at some point may need to offer a secondary which could dilute existing investors. However, the Company could also chose to get additional debt funding or project funding with minimal dilution. It is also also possible that the company will be able to penetrate the LED market sooner than expected which could generate the cash necessary for the company to continue on without having to raise additional financing in any form.
Conclusion
ForceField appears to be in the right industry at the right time. With the world’s focus turning to renewable energy, the potential that the company has is immense. LED lighting and clean electricity represent two of the fastest growing markets in the industry and it just so happens that ForceField is at the forefront of both. With the company’s smart use of resources, the recent technical strength, the latest strategic transactions in various countries, and the massive market potential, it appears that ForceField represents an excellent opportunity for investors.
For more information visit www.forcefieldenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Company Profile
ForceField Energy primarily operates in two distinct segments of renewable energy; LED lighting and waste heat recovery through its majority ownership of TransPacific Energy (“TPE”) a U.S.- based renewable energy provider that uses “waste heat” from various manufacturing and other sources to provide clean electricity. These are among the fastest growing areas of the worldwide renewable energy market with the total expected market to hit $500 billion by 2017.
Reason #1 – Recent Technical Strength
ForceField Energy has taken off in the past month as investors appear to have a better understanding of the company’s business and prospects. Over the past 30 days, shares of the company are up approximately 8%. The chart below shows the nice move that investors have enjoyed.
FNRG 1
In comparison, investors can look at the SPDR S&P 500 ETF Trust (SPY) to see how the broader market has performed. Over the same 30 day period, the overall market is only up approximately 3% as shown by the chart below.
FNRG 2
ForceField’s chart appears to be headed even higher given that the news highs have come on high volume trading days. Although it can be risky to buy at a new high, given the potential that the company has, investors may not want to miss the opportunity.
Reason #2 – LED Market Opportunity
Another part of the company’s business that should excite investors is the company’s participating in the LED market. FNRG recently has the exclusive North American, Latin American and European rights; and rest of world rights on a non-exclusive basis from a highly regarded LED manufacturer to distribute high-performance light emitting diode (LED) lighting fixtures used in many diverse applications. LED technology is expected to replace incandescent and fluorescent fixtures as it offers longer lifecycles, cost savings, and reduced energy consumption. LED technology is expected to have an even a stronger impact in the current economic environment where companies are aggressively seeking reductions in operating costs. LED lends itself well to these initiatives as both an immediate and long term solution.
The U.S. Department of Energy estimates that there are over 2.5 billion fixtures in commercial and industrial properties throughout the United States. The replacement cost of these fixtures and others worldwide could possibly exceed one trillion dollars. Given ForceField’s desirable position in this market, revenues could soar.
Reason #3 – NASDAQ Listing Offers Investors More Liquidity
On October 17th, ForceField Energy shares began trading on the NASDAQ. The listing should allow the company to gain more name recognition with traders and investors as the move provides greater liquidity and increased exposure to investment firms and money managers across the world. Given the company’s position within the renewable energy space, it is likely that momentum traders could soon pile in and give retail investors a reason to celebrate.
Risks
Although it appears ForceField has an incredible amount of potential, investors should know that with all micro-cap companies, especially in a risky industry such as renewable energy, raising cash is always challenging. Based on the company’s current balance sheet, relatively modest share count outstanding (16.3 million shares) and the Company’s demonstrated ability to raise capital on favorable terms ($6.0+ million over the past three years) with minimal dilution, it appears that Company has the ability to fund its operation in 2014 and going forward. In order to fully achieve their business plan it is possible that the Company at some point may need to offer a secondary which could dilute existing investors. However, the Company could also chose to get additional debt funding or project funding with minimal dilution. It is also also possible that the company will be able to penetrate the LED market sooner than expected which could generate the cash necessary for the company to continue on without having to raise additional financing in any form.
Conclusion
ForceField appears to be in the right industry at the right time. With the world’s focus turning to renewable energy, the potential that the company has is immense. LED lighting and clean electricity represent two of the fastest growing markets in the industry and it just so happens that ForceField is at the forefront of both. With the company’s smart use of resources, the recent technical strength, the latest strategic transactions in various countries, and the massive market potential, it appears that ForceField represents an excellent opportunity for investors.
For more information visit www.forcefieldenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CytRx Corp. (CYTR) – CEO Steven A. Kriegsman at the Helm
Los Angeles-based CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company’s oncology pipeline is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. The company also has rights to two additional drug candidates, tamibarotene and bafetinib.
At the helm of the company’s strong management team is president and CEO Steven A. Kriegsman, who has held the post since 2002. He also serves as a director of Galena Biopharma, Inc. (GALE) and chairman of Galena’s Compensation and Transaction Committees. Kriegsman previously served as director and chairman of Global Genomics from June 2000.
Kriegsman also is an inactive chairman and founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen, Inc., Closure Medical Corporation, Novoste Corp., Advanced Tissue Sciences, and Maxim Pharmaceuticals.
Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Kriegsman is a graduate of the Stanford Law School Directors’ College. He was formerly a Certified Public Accountant with KPMG in New York City, and served as a director and is the former chairman of the Audit Committee of Bradley Pharmaceuticals, Inc..
In 2006, Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association, and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University and New York University. He has also been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
For more information, see the company website at www.cytrx.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
At the helm of the company’s strong management team is president and CEO Steven A. Kriegsman, who has held the post since 2002. He also serves as a director of Galena Biopharma, Inc. (GALE) and chairman of Galena’s Compensation and Transaction Committees. Kriegsman previously served as director and chairman of Global Genomics from June 2000.
Kriegsman also is an inactive chairman and founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen, Inc., Closure Medical Corporation, Novoste Corp., Advanced Tissue Sciences, and Maxim Pharmaceuticals.
Kriegsman has a BS degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Kriegsman is a graduate of the Stanford Law School Directors’ College. He was formerly a Certified Public Accountant with KPMG in New York City, and served as a director and is the former chairman of the Audit Committee of Bradley Pharmaceuticals, Inc..
In 2006, Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association, and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University and New York University. He has also been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the California Health Initiative, the American Association of Dance Companies, and the Palisades-Malibu YMCA.
For more information, see the company website at www.cytrx.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
U.S. Bank to Offer Mitek’s Mobile Photo Balance Transfer™ Program to Mobile Customers
U.S. Bank, the lead bank of U.S. Bancorp (NYSE:USB), and Mitek Systems (NASDAQ:MITK), announced today that they have entered into an agreement in which U.S. Bank will offer Mitek’s Mobile Photo Balance Transfer™ to its mobile banking customers.
“U.S. Bank recognizes the power of mobile imaging and its ability to enhance our customers’ experience by giving them new and innovative ways to access and manage their banking relationship with us,” said Niti Badarinath, U.S. Bank’s senior vice president and head of mobile banking.
Beginning in November 2013, users will be able to easily take advantage of credit card balance transfer offers from U.S. Bank. All they have to do is simply snap a photo of a credit card payment coupon using their mobile device and send it to U.S. Bank to apply for a balance transfer to a U.S. Bank credit card. U.S. Bank will be the first leading bank to offer this innovative credit card service.
U.S. Bank will continue to enhance their customer’s mobile experience with Mitek’s MiSnap™ in the first quarter of 2014. MiSnap™ further simplifies the imaging process by automatically capturing the best possible photo without the customer needing to “snap” the picture.
“It is a pleasure working with U.S. Bank to redefine what consumers expect from their mobile banking experience,” said James DeBello, Mitek’s president and CEO. “Using our patented mobile balance transfer process, U.S. Bank can bring the power of mobile imaging to a traditional balance-transfer marketing program.”
For more information on U.S. Bank, please visit www.usbank.com. For more information on Mitek, please visit www.miteksystems.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“U.S. Bank recognizes the power of mobile imaging and its ability to enhance our customers’ experience by giving them new and innovative ways to access and manage their banking relationship with us,” said Niti Badarinath, U.S. Bank’s senior vice president and head of mobile banking.
Beginning in November 2013, users will be able to easily take advantage of credit card balance transfer offers from U.S. Bank. All they have to do is simply snap a photo of a credit card payment coupon using their mobile device and send it to U.S. Bank to apply for a balance transfer to a U.S. Bank credit card. U.S. Bank will be the first leading bank to offer this innovative credit card service.
U.S. Bank will continue to enhance their customer’s mobile experience with Mitek’s MiSnap™ in the first quarter of 2014. MiSnap™ further simplifies the imaging process by automatically capturing the best possible photo without the customer needing to “snap” the picture.
“It is a pleasure working with U.S. Bank to redefine what consumers expect from their mobile banking experience,” said James DeBello, Mitek’s president and CEO. “Using our patented mobile balance transfer process, U.S. Bank can bring the power of mobile imaging to a traditional balance-transfer marketing program.”
For more information on U.S. Bank, please visit www.usbank.com. For more information on Mitek, please visit www.miteksystems.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, October 25, 2013
PITOOEY!, Inc. (PTOO) Driving Business-to-Consumer Interactions through Revolutionary Mobile App
PITOOEY! Inc., a full-services digital marketing agency that offers customized marketing strategies to businesses that require a wholly new online presence or need the slightest tweaking, says that it is changing the way businesses and consumers are interacting with each other via a mobile platform.
Previously at the edge of forecasting mobile platform-based products for the entertainment and real estate marketplaces years before mobile apps such as Zillow and Broadwayworld made their mark, the company’s management team is now using its extensive knowledge and experience in mobile marketing trends to charter new waters—and to take the mobile platform-based customer loyalty advertising market in a whole new direction.
Namely, PTOO is pushing for market innovation with its flagship “consumer-centric” mobile app, Pitooey!, through its wholly owned subsidiary, PITOOEY! Mobile, Inc. The app is the first to allow easy, customized communications flow between consumer-facing businesses and consumers that serve businesses’ interest of greater customer acquisition and consumers’ interest in receiving information and content that fits their individual preferences at times they deem acceptable.
How the app works is simple. It allows consumers to locate their favorite businesses using an in-app profile-based search engine and then to subscribe to receive discount deals, message updates, or location-based information from them. They are able to control the timing of the content delivery as well. Businesses from all consumer-facing industries (e.g., retail locations, hospitality, and more) can sign up to be a part of the app’s online business community to take full advantage of these communication avenues. Since consumer-users opt in for and control their content delivery subscriptions, participating businesses clear the difficult hurdle of delivering timely, engaging product or service information that is fashioned to their target audiences’ interests.
Participant businesses can also add to or modify the messages and offers they send via a database, from which consumers receive the information based on their pre-chosen preferences. On the consumer-user side, Pitooey! features an easy-to-navigate interface for optimal information delivery flow.
Unlike many apps, PTOO says the Pitooey! app enables communication flow between businesses and consumers with the understanding of the importance of advertising and information delivery that is consumer interest-oriented. Currently on iTunes there are around 2,400 “lifestyle” apps, 2,300 “coupon” apps, and 3,100 “deal” apps, and 800 “loyalty” apps. Pitooey! takes all of these elements and combines them into one effortless, unprecedented customer loyalty app that the company says will help pioneer new levels of interaction between consumers and vendors in mobile marketing.
More information about the Pitooey! app can be found at: www.pitooey.com
For more information about PITOOEY! Inc. and its subsidiary, PITOOEY! Mobile, Inc., please visit: http://www.pitooeyinc.com/
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Previously at the edge of forecasting mobile platform-based products for the entertainment and real estate marketplaces years before mobile apps such as Zillow and Broadwayworld made their mark, the company’s management team is now using its extensive knowledge and experience in mobile marketing trends to charter new waters—and to take the mobile platform-based customer loyalty advertising market in a whole new direction.
Namely, PTOO is pushing for market innovation with its flagship “consumer-centric” mobile app, Pitooey!, through its wholly owned subsidiary, PITOOEY! Mobile, Inc. The app is the first to allow easy, customized communications flow between consumer-facing businesses and consumers that serve businesses’ interest of greater customer acquisition and consumers’ interest in receiving information and content that fits their individual preferences at times they deem acceptable.
How the app works is simple. It allows consumers to locate their favorite businesses using an in-app profile-based search engine and then to subscribe to receive discount deals, message updates, or location-based information from them. They are able to control the timing of the content delivery as well. Businesses from all consumer-facing industries (e.g., retail locations, hospitality, and more) can sign up to be a part of the app’s online business community to take full advantage of these communication avenues. Since consumer-users opt in for and control their content delivery subscriptions, participating businesses clear the difficult hurdle of delivering timely, engaging product or service information that is fashioned to their target audiences’ interests.
Participant businesses can also add to or modify the messages and offers they send via a database, from which consumers receive the information based on their pre-chosen preferences. On the consumer-user side, Pitooey! features an easy-to-navigate interface for optimal information delivery flow.
Unlike many apps, PTOO says the Pitooey! app enables communication flow between businesses and consumers with the understanding of the importance of advertising and information delivery that is consumer interest-oriented. Currently on iTunes there are around 2,400 “lifestyle” apps, 2,300 “coupon” apps, and 3,100 “deal” apps, and 800 “loyalty” apps. Pitooey! takes all of these elements and combines them into one effortless, unprecedented customer loyalty app that the company says will help pioneer new levels of interaction between consumers and vendors in mobile marketing.
More information about the Pitooey! app can be found at: www.pitooey.com
For more information about PITOOEY! Inc. and its subsidiary, PITOOEY! Mobile, Inc., please visit: http://www.pitooeyinc.com/
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
ForceField Energy, Inc. (FNRG) Takes Distinctive Lead in Key Segments of Renewable Energy Market
In 1978, the National Energy Act marked a monumental onset for the research and development of renewable energy, though the push for such standards started in the 1960s as Congress began to push legislation to protect natural resources (via the National Environmental Policy Act and Clean Air Act of 1969, for example). The renewable energy market in its relatively brief but rapid evolution has created a vast amount of competitive opportunities for renewable energy companies and their innovative technologies and applications.
Today, the multi-billion dollar renewable energy market is on the fast-track, expected to reach approximately $500 billion by 2017 with industrial waste heat recovery and conversion, and commercial LED lighting products leading the way.
U.S.-based small-cap renewable technology provider ForceField Energy, early-on recognized the industry’s trends and trajectory, and has positioned itself to obtain a meaningful market share in the aforementioned key segments.
Focusing on industrial waste heat recovery and conversion, ForceField has a 51 percent ownership in its TransPacific Energy (TPE) subsidiary, which has patented a technology that uses “waste heat” from various industry processes and other sources and converts it into clean electricity. The technology’s unique features unlock a myriad of new applications.
Through its exclusive multinational distribution agreement with Lightsky, a leading LED provider to large commercial and institutional users, ForceField also has a foothold in the LED lighting segment, which is growing at a 32- percent compound growth rate. Experts estimate that in the next five to 10 years, the world will transition from incandescent and fluorescent fixtures to LED technology to take advantage of reduced energy consumption and other advantageous variants.
As an international manufacturer, distributor and licensee of alternative energy products and solutions, ForceField’s operations and business model are planted in two of the fastest growing and most promising segments of the renewable energy market.
For more information visit: www.forcefieldenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Today, the multi-billion dollar renewable energy market is on the fast-track, expected to reach approximately $500 billion by 2017 with industrial waste heat recovery and conversion, and commercial LED lighting products leading the way.
U.S.-based small-cap renewable technology provider ForceField Energy, early-on recognized the industry’s trends and trajectory, and has positioned itself to obtain a meaningful market share in the aforementioned key segments.
Focusing on industrial waste heat recovery and conversion, ForceField has a 51 percent ownership in its TransPacific Energy (TPE) subsidiary, which has patented a technology that uses “waste heat” from various industry processes and other sources and converts it into clean electricity. The technology’s unique features unlock a myriad of new applications.
Through its exclusive multinational distribution agreement with Lightsky, a leading LED provider to large commercial and institutional users, ForceField also has a foothold in the LED lighting segment, which is growing at a 32- percent compound growth rate. Experts estimate that in the next five to 10 years, the world will transition from incandescent and fluorescent fixtures to LED technology to take advantage of reduced energy consumption and other advantageous variants.
As an international manufacturer, distributor and licensee of alternative energy products and solutions, ForceField’s operations and business model are planted in two of the fastest growing and most promising segments of the renewable energy market.
For more information visit: www.forcefieldenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cardium Therapeutics, Inc.’s (CXM) Generx® Addresses Global Cardiac Threat with Revolutionary Potential
Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of health sciences and regenerative medicine. Among other opportunities in its portfolio, the company’s lead clinical development product candidate, Generx®, is being developed to treat patients with advanced coronary artery disease (CAD). The market for this disease is tremendous – in 2012, CAD was the most common cause of death in the world, according to the World Health Organization.
While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.
Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.
Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.
Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.
For more information visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.
Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.
Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.
Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.
For more information visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Fibrocell Science (FCSC) Receives DEBRA of America’s Partner in Progress Award for Efforts to Develop Therapies for Epidermolysis Bullosa
Fibrocell Science, Inc., an autologous cell therapy company with its primary focus on developing innovative products for skin diseases and conditions, announced it has been honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA) for its recent work in developing potential therapies for epidermolysis bullosa (EB), a rare, genetic connective tissue disorder for which there is presently no treatment or cure. The award was accepted by company Chairman and CEO David Pernock at the 15th Annual DEBRA of America Benefit, which took place on Oct. 24 at the Museum of Modern Art in New York City.
Fibrocell Science was recognized for its exploration of the use of genetically modified, autologous fibroblast cells for recessive dystrophic epidermolysis bullosa (RDEB), which is the most severe form of EB. This work is part of the company’s exclusive channel collaboration with Intrexon Corporation to develop a treatment for RDEB.
The DEBRA of America Benefit marked the beginning of National Epidermolysis Bullosa Awareness Week, which takes place annually to increase awareness of EB, promote the need for a cure and spur advocacy initiatives on behalf of those who suffer the emotional, financial and physical burden of the disease. This year, National Epidermolysis Bullosa Awareness Week takes place Oct. 25-31.
For more information about epidermolysis bullosa, visit the DEBRA of America Web site at debra.org/whatiseb
For information about Fibrocell Science, visit www.fibrocellscience.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Fibrocell Science was recognized for its exploration of the use of genetically modified, autologous fibroblast cells for recessive dystrophic epidermolysis bullosa (RDEB), which is the most severe form of EB. This work is part of the company’s exclusive channel collaboration with Intrexon Corporation to develop a treatment for RDEB.
The DEBRA of America Benefit marked the beginning of National Epidermolysis Bullosa Awareness Week, which takes place annually to increase awareness of EB, promote the need for a cure and spur advocacy initiatives on behalf of those who suffer the emotional, financial and physical burden of the disease. This year, National Epidermolysis Bullosa Awareness Week takes place Oct. 25-31.
For more information about epidermolysis bullosa, visit the DEBRA of America Web site at debra.org/whatiseb
For information about Fibrocell Science, visit www.fibrocellscience.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Boston Therapeutics, Inc. (BTHE) and America’s Sugar Monster
The formal description for Boston Therapeutics is of a pharmaceutical company focused on the development of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. But the company’s potential, as an investment and in terms of its possible effect on the tens of millions of people with Type 2 diabetes, is far more dramatic. CEO David Platt is blunt about it, saying in a recent interview with the New Hampshire Union Leader “We believe that what we have in our hands is an absolute blockbuster”.
The blockbuster in question is the company’s one-of-a-kind proprietary polysaccharide, PAZ320, that represents a totally new way of treating type 2 diabetes, currently afflicting over 25 million people in the U.S. alone. PAZ320 is a chewable, locally acting complex carbohydrate-based compound that works in the gastrointestinal tract to directly block the enzymes that digest sugar. The demonstrated result is a dramatic reduction in the amount of glucose in the blood stream from carbohydrate rich meals. A phase II study of PAZ320 showed a 40 percent reduction of post-meal glucose in the blood of 45 percent of patients treated with PAZ320. There’s never been anything like it.
In spite of the enormous possibilities for Boston Therapeutics, CEO David Platt seems even more enthused about the development’s potential benefit for public health. With obesity becoming the country’s number one health issue, and even young people being faced with type 2 diabetes at levels never before experienced, Platt has an almost missionary zeal for taming the nation’s sugar monster. In the same newspaper interview, he emphasized the deadly and critical nature of the challenge, saying “It’s very simple. Sugar kills. End of story”.
For additional information, visit the company’s website at www.BostonTI.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The blockbuster in question is the company’s one-of-a-kind proprietary polysaccharide, PAZ320, that represents a totally new way of treating type 2 diabetes, currently afflicting over 25 million people in the U.S. alone. PAZ320 is a chewable, locally acting complex carbohydrate-based compound that works in the gastrointestinal tract to directly block the enzymes that digest sugar. The demonstrated result is a dramatic reduction in the amount of glucose in the blood stream from carbohydrate rich meals. A phase II study of PAZ320 showed a 40 percent reduction of post-meal glucose in the blood of 45 percent of patients treated with PAZ320. There’s never been anything like it.
In spite of the enormous possibilities for Boston Therapeutics, CEO David Platt seems even more enthused about the development’s potential benefit for public health. With obesity becoming the country’s number one health issue, and even young people being faced with type 2 diabetes at levels never before experienced, Platt has an almost missionary zeal for taming the nation’s sugar monster. In the same newspaper interview, he emphasized the deadly and critical nature of the challenge, saying “It’s very simple. Sugar kills. End of story”.
For additional information, visit the company’s website at www.BostonTI.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CytRx Corp. (CYTR) Continues to Build Oncology Portfolio, Headed by Lead Candidate Aldoxorubicin
CytRx is a biopharmaceutical research and development company with a particular focus on expanding its pipeline of oncology candidates in various stages of preclinical and clinical development.
Aldoxorubicin is the company’s novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.
CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.
CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.
The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.
CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.
For more information visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Aldoxorubicin is the company’s novel version of the commonly prescribed chemotherapeutic agent doxorubicin, which is a standard chemotherapeutic treatment for a variety of cancers and is used either alone or in combination with other chemotherapy agents. Aldoxorubicin differs in that it has the potential to safely deliver greater amounts of doxorubicin directly to the tumor compared with standard doxorubicin treatment, which the company believes could lead to improved efficacy.
CytRx holds the exclusive worldwide rights to aldoxorubicin. The candidate has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer.
CytRx recently announced favorable results from its phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors, and has initiated a phase 2b international clinical trial in patients with soft tissue sarcomas, and a phase 2 clinical trial in patients with pancreatic cancer.
The company in December plans to report top-line phase 2b data, which the company anticipates will provide the first direct clinical trial comparison of aldoxorubicin with native doxorubicin as a first-line treatment for soft tissue sarcoma.
CytRx also has rights to two additional drug candidates: tamibarotene, for which the company has completed evaluation in the ENABLE Phase 2 clinical trial in lymphocytic leukemia and for which it plans to seek a partnership for further development; and befetinib, which the company is evaluating for further development.
For more information visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
JetPay Corp. (JTPY) Payroll Services Expands Payroll, Tax Filing and More to Lancaster County, PA
JetPay’s subsidiary, JetPay® Payroll Services, announced today that it is expanding its state-of-the-art payroll, tax filing, and human resource services to businesses in Lancaster County, Pennsylvania. JetPay Payroll will be allocating staff and resources to businesses in Lancaster County, and has expanded its products and services to meet the specific needs of enterprises in that area.
With a 40-year presence in the Lehigh Valley, JetPay Payroll Services (formerly A.D. Computer) has been recognized for its award-winning customer service and innovative technology platform. JetPay has one of the most complete payments platforms in the country with mobile payments, Internet payments, and card-not-present payments, in addition to payroll, human resource and tax-filing services.
Now, as part of the family of companies under the JetPay Corporation banner, the subsidiary has added new products and services to its repertoire, including a human resource product called Workforce Today®, an online program that allows Human Resource personnel to track and manage such activities as job postings, applications, employee benefits, and much more.
The company is now also offering all the conveniences of end-to-end merchant transaction processing and card payment services, which will be offered through its sister company, JetPay Merchant Services.
Nick Antich, founder and CEO of JetPay Payroll Services, remarked, “We have traditionally focused on serving eastern Pennsylvania and western New Jersey where we are well known for our superior customer service and our individualized approach to meeting customers’ requirements. This year we are looking forward to growing our existing Lancaster County client base. We feel that Lancaster County is a perfect fit for us, as we are a local company that understands local business requirements.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
With a 40-year presence in the Lehigh Valley, JetPay Payroll Services (formerly A.D. Computer) has been recognized for its award-winning customer service and innovative technology platform. JetPay has one of the most complete payments platforms in the country with mobile payments, Internet payments, and card-not-present payments, in addition to payroll, human resource and tax-filing services.
Now, as part of the family of companies under the JetPay Corporation banner, the subsidiary has added new products and services to its repertoire, including a human resource product called Workforce Today®, an online program that allows Human Resource personnel to track and manage such activities as job postings, applications, employee benefits, and much more.
The company is now also offering all the conveniences of end-to-end merchant transaction processing and card payment services, which will be offered through its sister company, JetPay Merchant Services.
Nick Antich, founder and CEO of JetPay Payroll Services, remarked, “We have traditionally focused on serving eastern Pennsylvania and western New Jersey where we are well known for our superior customer service and our individualized approach to meeting customers’ requirements. This year we are looking forward to growing our existing Lancaster County client base. We feel that Lancaster County is a perfect fit for us, as we are a local company that understands local business requirements.”
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tonix Pharmaceuticals (TNXP) to Help Raise Fibromyalgia Awareness through Partnership with America Chronic Pain Association
Development-stage specialty pharmaceutical company Tonix Pharmaceuticals Holding Corp. announced it has become a corporate partner of the American Chronic Pain Association (ACPA) as part of that organization’s efforts to raise awareness about fibromyalgia, a syndrome increasingly identified in people who suffer chronic pain and believed to affect around 5 million people in the United States.
Currently, Tonix is developing TNX-102 SL, its lead clinical candidate for treating fibromyalgia and post-traumatic stress disorder. Tonix recently announced the initiation of the BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial – the first of two anticipated pivotal trials for TNX-102 SL 2.8 mg tablets in patients with fibromyalgia.
“We continue to strive to provide the best possible support, education in pain management skills, and resources to those who experience chronic pain in whatever form it takes,” said ACPA Executive Director and FounderPenney Cowan. “Partnerships with companies such as Tonix provide us with an important opportunity to inform consumers about the many elements of multidisciplinary pain management so that they may regain a sense of control in their lives and hope for their future.”
In April 2013, fibromyalgia was selected by the FDA as a disease to focus on for the next two fiscal years. A public meeting will be conducted by the FDA on Dec. 10, 2013 under Patient-Focused Development, an initiative involving acquisition of a better understanding of patients’ perspectives on the severity of the disease and available therapies for the condition. These activities are demonstrative of an increased awareness of fibromyalgia and its impact in the U.S. population.
For more information, visit www.tonixpharma.com or www.theacpa.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Currently, Tonix is developing TNX-102 SL, its lead clinical candidate for treating fibromyalgia and post-traumatic stress disorder. Tonix recently announced the initiation of the BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial – the first of two anticipated pivotal trials for TNX-102 SL 2.8 mg tablets in patients with fibromyalgia.
“We continue to strive to provide the best possible support, education in pain management skills, and resources to those who experience chronic pain in whatever form it takes,” said ACPA Executive Director and FounderPenney Cowan. “Partnerships with companies such as Tonix provide us with an important opportunity to inform consumers about the many elements of multidisciplinary pain management so that they may regain a sense of control in their lives and hope for their future.”
In April 2013, fibromyalgia was selected by the FDA as a disease to focus on for the next two fiscal years. A public meeting will be conducted by the FDA on Dec. 10, 2013 under Patient-Focused Development, an initiative involving acquisition of a better understanding of patients’ perspectives on the severity of the disease and available therapies for the condition. These activities are demonstrative of an increased awareness of fibromyalgia and its impact in the U.S. population.
For more information, visit www.tonixpharma.com or www.theacpa.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, October 24, 2013
Smith Micro Software, Inc. (SMSI) Partners with in Motion Technology to Extend In-Vehicle Mobile Hotspot Solution
Smith Micro Software, whose portfolio of wireless solutions cover numerous aspects of broadband connectivity management, reported a key partnership agreement today with mobile enterprise network leader, In Motion Technology, which will ultimately result in a huge operational improvement for public safety agencies and first responders by extending the reach of in-vehicle routers to cover mobile devices.
The partnership fuses SMSI’s powerful carrier-agnostic and device-agnostic connection management platform, the client-server solution known as QuickLink® Mobility, and In Motion’s onBoard Connection Manager (oCM) software, resulting in comprehensive fabric connectivity solution that allows devices to seamlessly transition between external sources and in-vehicle routers. The mobile enterprise network technology of In Motion, enhanced by SMSI’s connection management software, extends the range of the in-vehicle router while maintaining a rock-solid, secure connection to the enterprise network across 3G/4G and Wi-Fi.
Basically, the SMSI software allows the in-vehicle coverage area to function as a wider mobile hotspot, granting mobile devices the ability to move seamlessly on and off of the in-vehicle network access point in an extremely consistent and secure manner. The use of QuickLink Mobility is ideal in this case as it provides incredible flexibility through support of multiple carriers, while also granting IT admins real-time situational awareness and control over all mobile devices/expenses, thanks to its single client architecture. Compatible with over 400 devices and able to utilize everything from WWAN and Wi-Fi to Ethernet and even dial-up, QuickLink Mobility erases all the connectivity barriers users are accustomed to and, as a platform, comprises a highly customizable connection and security envelope, despite its unprecedented ease of use.
This is the kind of field-ready solution we want for our first responders and public safety agencies, a combined solution that is utterly simple and easy to use, with optimum security and reliability, yet which still allows for the evolution of a BYOD (bring your own device) workplace. A BYOD workplace with comprehensive over watch capability for admins across the entire device ecosystem and QuickLink Mobility is actually just one piece of SMSI’s impressive Enterprise Mobility platform, which is designed to handle both commercial and public sector organization needs. Key aspects of this particular implementation for public safety, like the ability to hide unauthorized networks and enforce connection to the In Motion node as the primary network, stand out as major selling points. Essential ease of use features like Single-sign-on and Connect-before-login make access a breeze and delimit password failures as well, again making the implementation very attractive to the target market.
Chief Strategy Officer for SMSI, Daniel Rawlings, underscored In Motion’s technology leadership in this space, where they have gained quite the reputation for delivering mission-critical performance capabilities to field personnel such as law enforcement, allowing officers to take at least one concern out of the equation when it comes serving the public. The marriage of QuickLink Mobility with In Motion’s in-vehicle network access point frees devices like laptops and tablets to roam with personnel, vastly improving their coverage/performance at a given incident, where often every second could mean the difference between life and death.
VP of Sales over at In Motion Technology, Tony Morris, echoed these sentiments and praised the carrier-grade connection management solutions demonstrated by SMSI via multiple proven deployments with public safety agencies, citing such evidence as obvious hallmarks of a successful partnership. The two sets of technology complement each other marvelously well according to Mr. Morris and this deal significantly improves the appeal of the In Motion solution for first responders in his eyes.
For more info on Smith Micro Software, visit www.SmithMicro.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The partnership fuses SMSI’s powerful carrier-agnostic and device-agnostic connection management platform, the client-server solution known as QuickLink® Mobility, and In Motion’s onBoard Connection Manager (oCM) software, resulting in comprehensive fabric connectivity solution that allows devices to seamlessly transition between external sources and in-vehicle routers. The mobile enterprise network technology of In Motion, enhanced by SMSI’s connection management software, extends the range of the in-vehicle router while maintaining a rock-solid, secure connection to the enterprise network across 3G/4G and Wi-Fi.
Basically, the SMSI software allows the in-vehicle coverage area to function as a wider mobile hotspot, granting mobile devices the ability to move seamlessly on and off of the in-vehicle network access point in an extremely consistent and secure manner. The use of QuickLink Mobility is ideal in this case as it provides incredible flexibility through support of multiple carriers, while also granting IT admins real-time situational awareness and control over all mobile devices/expenses, thanks to its single client architecture. Compatible with over 400 devices and able to utilize everything from WWAN and Wi-Fi to Ethernet and even dial-up, QuickLink Mobility erases all the connectivity barriers users are accustomed to and, as a platform, comprises a highly customizable connection and security envelope, despite its unprecedented ease of use.
This is the kind of field-ready solution we want for our first responders and public safety agencies, a combined solution that is utterly simple and easy to use, with optimum security and reliability, yet which still allows for the evolution of a BYOD (bring your own device) workplace. A BYOD workplace with comprehensive over watch capability for admins across the entire device ecosystem and QuickLink Mobility is actually just one piece of SMSI’s impressive Enterprise Mobility platform, which is designed to handle both commercial and public sector organization needs. Key aspects of this particular implementation for public safety, like the ability to hide unauthorized networks and enforce connection to the In Motion node as the primary network, stand out as major selling points. Essential ease of use features like Single-sign-on and Connect-before-login make access a breeze and delimit password failures as well, again making the implementation very attractive to the target market.
Chief Strategy Officer for SMSI, Daniel Rawlings, underscored In Motion’s technology leadership in this space, where they have gained quite the reputation for delivering mission-critical performance capabilities to field personnel such as law enforcement, allowing officers to take at least one concern out of the equation when it comes serving the public. The marriage of QuickLink Mobility with In Motion’s in-vehicle network access point frees devices like laptops and tablets to roam with personnel, vastly improving their coverage/performance at a given incident, where often every second could mean the difference between life and death.
VP of Sales over at In Motion Technology, Tony Morris, echoed these sentiments and praised the carrier-grade connection management solutions demonstrated by SMSI via multiple proven deployments with public safety agencies, citing such evidence as obvious hallmarks of a successful partnership. The two sets of technology complement each other marvelously well according to Mr. Morris and this deal significantly improves the appeal of the In Motion solution for first responders in his eyes.
For more info on Smith Micro Software, visit www.SmithMicro.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
UQM Technologies (UQM) Motor and Controller Featured in Chip Yates’ Guinness World Record Setting Electric Airplane
UQM Technologies, a developer and manufacturer of power-dense, high-efficiency electric motors, generators, and power electronic controllers for the automotive, commercial truck, bus, marine, and military markets, has congratulated Chip Yates on setting two new electric-powered airplane-related Guinness World Records at the Capital Air Show earlier this month. The all-electric plane he used for his record setting performance features a UQM PowerPhase® motor and controller to facilitate powerful and efficient fuel-free flight.
“Yates has taken electric-powered transportation to new heights with his latest round of records,” said Eric R. Ridenour, President and Chief Executive Officer of UQM Technologies, Inc. “Unlike internal-combustion engines, the power output of our electric motor is not affected by altitude, providing steady and consistent power.”
During his performance at the air show, Yates climbed to 500 meters in only 62.58 seconds from a complete stop, setting a Guinness World Record for speed of climb to altitude in an electric plane. He also flew the aircraft at record speeds over a one kilometer course averaging two passes, one from each direction, reaching 220.9 mph on the first pass and 212.9 mph on the second. The average of the two passes represents a Guinness World record of 216.9.
“We’re extremely excited by all these world records and their implications for potential commercial and military applications of electric vehicle technology,” said Yates. This makes a total of 16 electric vehicle world records achieved by Yates and his team.
UQM Technologies offers a range of production-validated electric motors and controllers in addition to being able to meet the needs of custom, small-volume projects. All UQM systems offer high efficiency with power-dense motors and advanced controllers.
For further information, please visit www.uqm.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Yates has taken electric-powered transportation to new heights with his latest round of records,” said Eric R. Ridenour, President and Chief Executive Officer of UQM Technologies, Inc. “Unlike internal-combustion engines, the power output of our electric motor is not affected by altitude, providing steady and consistent power.”
During his performance at the air show, Yates climbed to 500 meters in only 62.58 seconds from a complete stop, setting a Guinness World Record for speed of climb to altitude in an electric plane. He also flew the aircraft at record speeds over a one kilometer course averaging two passes, one from each direction, reaching 220.9 mph on the first pass and 212.9 mph on the second. The average of the two passes represents a Guinness World record of 216.9.
“We’re extremely excited by all these world records and their implications for potential commercial and military applications of electric vehicle technology,” said Yates. This makes a total of 16 electric vehicle world records achieved by Yates and his team.
UQM Technologies offers a range of production-validated electric motors and controllers in addition to being able to meet the needs of custom, small-volume projects. All UQM systems offer high efficiency with power-dense motors and advanced controllers.
For further information, please visit www.uqm.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Chanticleer Holdings, Inc. (HOTR) Finalizes Stock Purchase Agreement for Nottingham, England Hooters Location
Chanticleer Holdings, a U.S.-based franchisee of international Hooters® restaurants and a minority owner in the privately held parent company of the Hooters brand, Hooters of America, today announced it has finalized the Stock Purchase Agreement for complete ownership of the shares of West End Wings Limited (“WEW”), for a total purchase price of $3.15 million. The release disclosed the seller of WEW as Manchester Wings Limited.
Prior to the transaction, WEW wholly owned the Nottingham, UK Hooters restaurant location operations. As part of the transaction, all leasehold and franchise rights to the location will be transferred to Chanticleer Holdings, for which November 5, 2013 has been set as a date for final closing and execution of all remaining documents. The execution of this agreement is in line with the Binding Letter of Intent signed on August 2, 2013.
This agreement is Chanticleer Holdings’ latest step forward in its ambitious plans for continued rapid international growth. The Nottingham location is the company’s second European and seventh Hooters location. It is also one of Hooters’ leading international locations as well as a popular destination for watching the exploits of the many local sporting teams and taking a break from the area’s many tourist attractions. The restaurant has 340 seats, including two outdoor patio areas that accommodate a total of 80 customers. WEW has owned and operated this location for the last 15 years, and the restaurant’s current management team will continue to keep the restaurant running under Chanticleer’s new ownership.
Mike Pruitt, CEO and President of Chanticleer Holdings, commented, “Nottingham has been a stellar location for the iconic Hooters brand, and we look forward to continuing its excellence in service and performance. The Nottingham location is a tremendous step forward in our plans to expand Chanticleer’s European Hooters’ footprint and to achieve profitability, and I look forward to being at the Nottingham restaurant for the closing of the transaction. We thank those who believed in this transaction and Chanticleer’s plans and provided us the capital to make this happen.”
Johnny Goard, Owner of the Hooters restaurant in Nottingham, England, stated, “Nottingham is a great store with a strong management team and staff that are sure to thrive for many years to come.”
For more information about Chanticleer Holdings, visit www.chanticleerholdings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Prior to the transaction, WEW wholly owned the Nottingham, UK Hooters restaurant location operations. As part of the transaction, all leasehold and franchise rights to the location will be transferred to Chanticleer Holdings, for which November 5, 2013 has been set as a date for final closing and execution of all remaining documents. The execution of this agreement is in line with the Binding Letter of Intent signed on August 2, 2013.
This agreement is Chanticleer Holdings’ latest step forward in its ambitious plans for continued rapid international growth. The Nottingham location is the company’s second European and seventh Hooters location. It is also one of Hooters’ leading international locations as well as a popular destination for watching the exploits of the many local sporting teams and taking a break from the area’s many tourist attractions. The restaurant has 340 seats, including two outdoor patio areas that accommodate a total of 80 customers. WEW has owned and operated this location for the last 15 years, and the restaurant’s current management team will continue to keep the restaurant running under Chanticleer’s new ownership.
Mike Pruitt, CEO and President of Chanticleer Holdings, commented, “Nottingham has been a stellar location for the iconic Hooters brand, and we look forward to continuing its excellence in service and performance. The Nottingham location is a tremendous step forward in our plans to expand Chanticleer’s European Hooters’ footprint and to achieve profitability, and I look forward to being at the Nottingham restaurant for the closing of the transaction. We thank those who believed in this transaction and Chanticleer’s plans and provided us the capital to make this happen.”
Johnny Goard, Owner of the Hooters restaurant in Nottingham, England, stated, “Nottingham is a great store with a strong management team and staff that are sure to thrive for many years to come.”
For more information about Chanticleer Holdings, visit www.chanticleerholdings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Jameson Stanford Resources Corp. (JMSN) Closes $500,000 Series B Bridge Financing
Jameson Stanford Resources, an emerging metals and minerals exploration company focused on sites in southwestern and central Utah, today reports that it has closed $500,000 of Series B Convertible Redeemable Promissory Notes (“Series B Notes”) due October 31, 2015.
The Series B Notes are secured by JMSN’s mining claims and mineral leases related to the Chopar Mining property, Star Mining District, located in Beaver County, Utah. The Series B Notes share the security interest on a pari passu basis with $500,000 of Series A convertible redeemable promissory notes issued on August 19, 2013, and with $500,000 of Series B Notes that are currently being offered for sale by the company on similar terms.
JMSN intends to use the proceeds of this financing primarily to fund ongoing mineral exploration activities and for general working capital purposes.
“This Series B Notes closing augments the company’s capital funding for our minerals exploration activities at the Star Mountain project,” JMSN president and CEO Michael Stanford stated in the news release. “We remain confident in our belief that our ongoing exploration activities at the Wild Bill Mine site will allow us to begin operations in late 2013. We are continuing our exploration activities as we secure additional financing.”
For more information visit: www.JamesonStanford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Series B Notes are secured by JMSN’s mining claims and mineral leases related to the Chopar Mining property, Star Mining District, located in Beaver County, Utah. The Series B Notes share the security interest on a pari passu basis with $500,000 of Series A convertible redeemable promissory notes issued on August 19, 2013, and with $500,000 of Series B Notes that are currently being offered for sale by the company on similar terms.
JMSN intends to use the proceeds of this financing primarily to fund ongoing mineral exploration activities and for general working capital purposes.
“This Series B Notes closing augments the company’s capital funding for our minerals exploration activities at the Star Mountain project,” JMSN president and CEO Michael Stanford stated in the news release. “We remain confident in our belief that our ongoing exploration activities at the Wild Bill Mine site will allow us to begin operations in late 2013. We are continuing our exploration activities as we secure additional financing.”
For more information visit: www.JamesonStanford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, October 23, 2013
World Energy Solutions, Inc. (XWES) World Energy Exchange Helps GSA Some $5.5M on Energy
World Energy Solutions, which provides energy management services and carbon market like their World Energy Exchange® that fully supports the first mandatory market-based greenhouse gas emissions regulatory program, the Regional Greenhouse Gas Initiative, announced today that the company has helped federal government workplace solutions provider GSA (General Services Administration), New England Region, to lock down some 920M kWh of electricity via competitive World Energy Exchange online auctions.
This powerful trading framework allowed XWES to handle 168 bids in under two hours from either different suppliers, vetting a whole range of products and terms in a fair and wholly transparent manner and netting over 69M of those aforementioned kWh from renewables. The lion’s share of the kWh thusly procured will go to infrastructure of 119 federal accounts across Connecticut, Maine, Massachusetts, New Hampshire, and Rhode Island.
This strategic procurement was extremely successful and represents the first time federal accounts in the Commonwealth of Massachusetts were included, resulting in a quadrupling of the load auctioned via XWES by the GSA, New England Region, back in 2011. This auction managed to bring in seven new 36-month contracts covering block and index, as well as fixed-price products, 7.5% of which is green energy and in total, we are talking a hefty savings of over $5.5M compared to the prior agreements the participating agencies had on the table.
Yet another case where XWES proves they have the superior architecture and the requisite skill set to deliver (delivery start slated for March 2014 ) big savings and improved energy profiles for the exacting requirements of federal agencies. The block and index product in particular is noteworthy as it was designed specifically for the unique nuances of the New England power market and really incentivizes the agencies to bleed off excess load during periods of peak pricing. Agencies like the American Red Cross, Bureau of Prisons, and the Department of State participated in this procurement, as well as the VA and Hanscom Air Force Base.
Today’s announcement marks a long and distinguished track record of successes with GSA for the company stretching back to 2001, during which XWES has delivered a whopping 13B kWh plus of electrical supply and some 170M dekatherms (1 Dth is equal to 1M BTUs or approximately 293 kWh) of natural gas supply.
VP of Government operations for XWES, Jonathan Harvey, called the deal a real milestone, both for XWES and for the GSA. Harvey thanked the GSA team and their outstanding energy personnel for helping to execute an extremely successful procurement that really breaks the mold in terms of using innovative pricing products that can leverage both investments in demand-side management, as well as those in supply-side buying strategies that have been cultivated by these federal agencies.
Harvey pointed proudly to the block and index product that only fixes prices during the months when prices are highest, while allowing the price to float for the remainder when prices are often up to more than half as much, as a prime example of how XWES can help federal agencies save money, especially in times of extreme budgetary duress.
Read more about World Energy Solutions, Inc. at www.WorldEnergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This powerful trading framework allowed XWES to handle 168 bids in under two hours from either different suppliers, vetting a whole range of products and terms in a fair and wholly transparent manner and netting over 69M of those aforementioned kWh from renewables. The lion’s share of the kWh thusly procured will go to infrastructure of 119 federal accounts across Connecticut, Maine, Massachusetts, New Hampshire, and Rhode Island.
This strategic procurement was extremely successful and represents the first time federal accounts in the Commonwealth of Massachusetts were included, resulting in a quadrupling of the load auctioned via XWES by the GSA, New England Region, back in 2011. This auction managed to bring in seven new 36-month contracts covering block and index, as well as fixed-price products, 7.5% of which is green energy and in total, we are talking a hefty savings of over $5.5M compared to the prior agreements the participating agencies had on the table.
Yet another case where XWES proves they have the superior architecture and the requisite skill set to deliver (delivery start slated for March 2014 ) big savings and improved energy profiles for the exacting requirements of federal agencies. The block and index product in particular is noteworthy as it was designed specifically for the unique nuances of the New England power market and really incentivizes the agencies to bleed off excess load during periods of peak pricing. Agencies like the American Red Cross, Bureau of Prisons, and the Department of State participated in this procurement, as well as the VA and Hanscom Air Force Base.
Today’s announcement marks a long and distinguished track record of successes with GSA for the company stretching back to 2001, during which XWES has delivered a whopping 13B kWh plus of electrical supply and some 170M dekatherms (1 Dth is equal to 1M BTUs or approximately 293 kWh) of natural gas supply.
VP of Government operations for XWES, Jonathan Harvey, called the deal a real milestone, both for XWES and for the GSA. Harvey thanked the GSA team and their outstanding energy personnel for helping to execute an extremely successful procurement that really breaks the mold in terms of using innovative pricing products that can leverage both investments in demand-side management, as well as those in supply-side buying strategies that have been cultivated by these federal agencies.
Harvey pointed proudly to the block and index product that only fixes prices during the months when prices are highest, while allowing the price to float for the remainder when prices are often up to more than half as much, as a prime example of how XWES can help federal agencies save money, especially in times of extreme budgetary duress.
Read more about World Energy Solutions, Inc. at www.WorldEnergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)